Introduction {#s1}
============

The covalent and reversible modification of histones allows cells to establish stable and heritable patterns of gene expression without any changes to their genetic blueprint. Histone H3 lysine nine methylation (H3K9me) is a conserved mark of transcriptional silencing that is associated with the formation of specialized domains called heterochromatin. Heterochromatin formation is critical for centromere and telomere function, silencing of transposons and repetitive DNA elements, and for maintaining lineage-specific patterns of gene expression ([@bib20]; [@bib38]). It is widely assumed that a delicate interplay between histone modification readers, writers, and erasers regulates the establishment and maintenance of epigenetic states ([@bib2]). In fission yeast, the establishment of H3K9 methylation requires the enzymatic activity of a conserved methyltransferase, Clr4^Suv39h^ ([@bib41]). H3K9 methylation acts as a platform to recruit chromatin effector proteins with reader domains. Two HP1 homologs, Swi6^HP1^ and Chp2^HP1^, are involved in H3K9 methylation binding and have distinct, non-overlapping functions during transcriptional silencing ([@bib37]). Ultimately, factors such as Epe1, a putative histone demethylase, promote epigenetic erasure, thus reversing H3K9 methylation and transcriptional gene silencing ([@bib5]; [@bib50]).

The sequence-specific recruitment of Clr4^Suv39h^ restricts heterochromatin establishment to distinct sites in the genome, such as the centromeres, telomeres, and the mating-type locus ([@bib9]; [@bib21]; [@bib54]; [@bib55]). Once established, H3K9 methylation spreads to silence genes that are distant from heterochromatin nucleation centers. H3K9me spreading depends on the read-write activity of Clr4^Suv39h^ ([@bib1]; [@bib61]). Two conserved, structural attributes of Clr4^Suv39h^ mediate this process: a conserved chromodomain that recognizes and binds to H3K9me and an enzymatic SET domain that is involved in catalysis ([@bib25]). The ability of Clr4^Suv39h^ to bind to the product of its enzymatic activity enables H3K9 methylated histones to serve as carriers of epigenetic information ([@bib3]; [@bib40]). Following DNA replication, H3K9 methylated histones that are partitioned between daughter DNA strands serve as templates to mark newly deposited histones.

H3K9 methylation acts as a multivalent platform that recruits the HP1 homolog, Swi6^HP1^ to sites of constitutive heterochromatin ([@bib18]; [@bib19]). HP1 proteins have a conserved architecture consisting of a chromodomain (CD) that is involved in H3K9 methylation binding and a dimerization domain called the chromoshadow domain (CSD) that mediates protein-protein interactions ([@bib7]; [@bib16]). The oligomerization of HP1 proteins promotes formation of higher-order chromatin complexes that exhibit phase separated, liquid-like properties in vitro and in cells ([@bib31]; [@bib44]; [@bib49]). Swi6^HP1^ interacts with a broad spectrum of agonists and antagonists that influence epigenetic silencing. Most notably, recruitment of Epe1, a putative histone demethylase that opposes heterochromatin formation, is dependent on Swi6^HP1^ ([@bib5]; [@bib63]). Loss of Epe1 leads to increased heterochromatin spreading beyond normal boundary sequences, inheritance of H3K9 methylation via sequence-independent pathways, increased cell to cell variation in H3K9 methylation patterns, and acquisition of adaptive epigenetic traits ([@bib3]; [@bib5]; [@bib40]; [@bib48]; [@bib51]; [@bib57]; [@bib63]; [@bib62]). Despite its critical role in heterochromatin regulation, how Epe1 exerts its anti-silencing function in cells remains mysterious ([@bib51]).

Histone demethylases have prominent roles in regulating the reversibility of epigenetic states ([@bib26]; [@bib59]). Changes in their expression lead to widespread chromatin reorganization, which alters both the prognosis and treatment of diseases such as cancer ([@bib34]). Epe1 most closely resembles JumonjiC (JmjC) domain containing proteins that use Fe (II) and α-ketoglutarate as co-factors to catalyze histone demethylation ([@bib52]). Unlike active histone demethylases, where an HxD/E....H motif is involved in Fe (II) coordination, Epe1 harbors a non-canonical HXE....Y motif ([@bib52]). Although Epe1 shares conserved features with other histone demethylases at the amino acid level, there is no biochemical evidence to support the notion that Epe1 has any in vitro enzymatic activity. Epe1 purified from fission yeast cells, or a recombinant source (insect cells), exhibits no H3K9 demethylase activity in vitro ([@bib52]; [@bib63]). However, point mutations of amino acid residues involved in Fe (II) or α-ketoglutarate binding affect Epe1 activity in cells and lead to heterochromatin spreading beyond normal boundary sequences ([@bib51]). These conflicting lines of biochemical and genetic data have prompted several alternative explanations for how Epe1 might fulfill its anti-silencing role. These models include the possibility that Epe1 acts as a protein hydroxylase which targets non-histone proteins such as Swi6^HP1^, regulates the activity of the multi-subunit H3K9 methyltransferase CLRC complex, or functions as an H3K9 demethylase when in complex with Swi6^HP1^ ([@bib4]; [@bib24]; [@bib51]; [@bib63]). Although these models represent attractive possibilities for how Epe1 regulates heterochromatin, there is no direct evidence to suggest that any of these proteins represent bonafide enzymatic targets. An alternative hypothesis is that Epe1 has a non-enzymatic function that regulates heterochromatin spreading and epigenetic inheritance. In support of this hypothesis, the overexpression of Fe (II) and α-ketoglutarate binding mutants of Epe1 suppresses heterochromatin spreading defects observed in *epe1Δ* strains ([@bib51]; [@bib63]). Hence, co-factor binding mutants of Epe1 can act as multi-copy suppressors of epigenetic silencing despite the presumptive loss of enzymatic activity.

In this study, we discovered that the putative catalytic JmjC domain of Epe1 is, at least in part, dispensable for its anti-silencing function in cells. The C-terminus of Epe1 directly interacts with Swi6^HP1^ and its interaction in the context of full-length Epe1 is regulated by H3K9 methylation. Expressing the Epe1 C-terminus alone is sufficient to reverse heterochromatin establishment and attenuate epigenetic inheritance. We propose that a *cis* interaction between the Epe1 N- and C-terminus inhibits Swi6^HP1^ binding. H3K9 methylation binding attenuates this intramolecular interaction and promotes Swi6^HP1^ binding. A requirement for H3K9 methylation to stabilize a complex comprising Epe1 and Swi6^HP1^ restricts their interaction to a heterochromatin-specific context. Our work highlights the versatile, non-canonical ways in which histone demethylases can oppose establishment and maintenance of epigenetic states.

Results {#s2}
=======

A point mutation within the catalytic JmjC domain of Epe1 affects its localization at sites of constitutive heterochromatin {#s2-1}
---------------------------------------------------------------------------------------------------------------------------

JmjC domain-containing proteins require Fe (II) and α-ketoglutarate as co-factors to catalyze histone demethylation. Aligning the primary amino acid sequences of active histone demethylases with Epe1 reveals a naturally occurring histidine to tyrosine substitution (Y370) within a conserved triad of amino acid residues that coordinate iron ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). We tested whether the activity of Epe1 in cells is dependent on this non-conserved tyrosine residue (Y370). To measure Epe1 activity, we used a reporter gene assay that provides a direct read-out of epigenetic inheritance. In this system, an H3K9 methyltransferase, Clr4^Suv39h^ is fused to a DNA binding protein, TetR. This fusion protein is recruited to an ectopic site where ten Tet operator sites (*10X TetO*) are placed upstream of a reporter gene, *ade6^+^* ([Figure 1A](#fig1){ref-type="fig"}). Establishment in the absence of tetracycline results in the appearance of red colonies. The sequence-specific initiator, TetR-Clr4-I, dissociates in the presence of tetracycline, enabling us to test whether cells can maintain silencing in the absence of continuous initiation. Wild-type cells are initially red in medium not containing tetracycline (−tetracycline medium), indicating that the reporter gene is initially silenced (establishment). Cells that have a functional copy of Epe1 turn white and exhibit no maintenance when plated on +tetracycline-containing medium. The ability of fission yeast cells to autonomously propagate epigenetic silencing is exquisitely sensitive to Epe1 activity. We observed epigenetic maintenance in cells where Epe1 is either deleted or inactivated, resulting in red or sectored colonies on +tetracycline-containing medium ([@bib3]; [@bib40]).

![Point mutation within the catalytic JmjC domain of Epe1 affects protein localization at sites of constitutive heterochromatin.\
(**A**) Reporter system to measure epigenetic inheritance. TetR-Clr4-I binding (−tetracycline) leads to ectopic establishment of H3K9 methylation. Addition of tetracycline promotes TetR-Clr4-I dissociation, enabling us to measure epigenetic inheritance of H3K9 methylation. (**B**) Color-based assay to detect establishment and maintenance of epigenetic states. The establishment of epigenetic silencing (−tetracycline) leads to the appearance of red colonies. Epigenetic inheritance, indicated by red or sectored colonies, (+tetracycline) is critically dependent on Epe1 activity. Point mutations within the JmjC domain of Epe1 disrupt its anti-silencing function in cells, leading to the appearance of red or sectored colonies. (**C**) ChIP-qPCR measurements of H3K9me2 levels at the ectopic site (*10X tetO ade6+*) during establishment (−tetracycline) in different Epe1 mutant backgrounds (N = 2). Error bars represent standard deviations. (**D**) ChIP-qPCR measurements of H3K9me2 levels at the ectopic site (*10X tetO ade6+*) during maintenance (+tetracycline) in different Epe1 mutant backgrounds (N = 2). Error bars represent standard deviations. (**E**) Live cell imaging of Epe1 and Swi6^HP1^. Four images in each case correspond to DIC, 488 excitation, 560 excitation, and overlay of the three emission channels. mNeonGreen-Epe1 and mCherry- Swi6^HP1^ form co-localized foci in green and red emission channels, respectively (see white arrows). (**F**) mNeonGreen-Epe1 Y307A fails to form any foci and instead exhibits a diffuse signal that permeates the nucleus. mCherry- Swi6^HP1^ forms foci corresponding to sites of constitutive heterochromatin.](elife-53155-fig1){#fig1}

Alanine substitutions of amino acid residues involved in Fe (II) or α-ketoglutarate binding (*epe1 H297A* and *epe1 Y307A*, respectively) disrupt co-factor binding, resulting in the concomitant loss of Epe1 activity. When expressed at endogenous levels, these mutants form red or sectored colonies on +tetracycline-containing medium and resemble *epe1Δ* cells ([Figure 1B](#fig1){ref-type="fig"}). Replacing the non-conserved tyrosine residue in Epe1 with alanine (*epe1 Y370A*) leads to a similar loss of function phenotype. Hence, despite the lack of conservation, a natural tyrosine substitution within the JmjC domain of Epe1 is essential for its anti-silencing function in cells. We used chromatin immunoprecipitation assays followed by qPCR to measure H3K9me2 levels associated with the reporter gene locus before and after tetracycline addition. Both wild-type and Epe1 mutant strains exhibit high levels of H3K9me2 during establishment ([Figure 1C](#fig1){ref-type="fig"}). However, wild-type cells lose H3K9me2 approximately 24 h after tetracycline addition. In contrast, Epe1 mutants that exhibit a red or sectored phenotype upon +tetracycline addition retain high levels of H3K9 methylation at the ectopic site ([Figure 1D](#fig1){ref-type="fig"}). We verified that the expression level of all Epe1 mutant proteins is equal relative to an actin loading control. Hence, neither overexpression artifacts nor changes in protein stability contribute to the maintenance-specific phenotype we observed in our genetic assays ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}).

Epe1 is localized at sites of constitutive heterochromatin through its interactions with Swi6^HP1^ ([@bib5]; [@bib63]). We imaged Epe1 and Swi6^HP1^ in live fission yeast cells using fluorescent protein fusions. We labeled Epe1 with mNeonGreen and Swi6^HP1^ with mCherry. This labeling scheme allows Epe1 and Swi6^HP1^ to be visualized in separate green and red emission channels, respectively. Both fusion proteins were expressed from their endogenous promoters to discount any possible overexpression artifacts. mCherry-Swi6^HP1^ typically exhibits two or three bright foci in individual cells ,corresponding to sites of constitutive heterochromatin (centromeres and telomeres). mNeonGreen-Epe1 co-localizes with mCherry-Swi6^HP1^ as evidenced by the significant overlap between the bright foci that appear green and red emission channels (see white arrows). The overlay also reveals that clusters of Epe1 and Swi6 are co-localized ([Figure 1E](#fig1){ref-type="fig"}). Surprisingly, an Epe1 co-factor binding mutant, mNeonGreen-Epe1 Y307A, fails to co-localize with mCherry-Swi6^HP1^. Instead, the mutant protein exhibits a diffuse green signal within the nucleus and a complete lack of nuclear foci that co-localize with Swi6^HP1^ ([Figure 1F](#fig1){ref-type="fig"}). The elevated signal in the cytoplasm could not be attributed to a defect in nuclear localization as cells that do not express any mNeonGreen-Epe1 also exhibit high levels of autofluorescence in the green channel ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Hence, in addition to affecting any putative enzymatic functions, a co-factor binding mutation within the JmjC domain of Epe1 eliminates protein localization at sites of constitutive heterochromatin.

Mutations within the JmjC domain disrupt a direct interaction between Epe1 and Swi6^HP1^ {#s2-2}
----------------------------------------------------------------------------------------

We hypothesized that the absence of heterochromatin localization in the Epe1 JmjC mutant could reflect a loss of Swi6^HP1^ binding. We used a co-immunoprecipitation assay to compare the interaction between Epe1 and Swi6^HP1^ in wild-type and Epe1 mutant cells. We expressed an Epe1-3X FLAG fusion protein at endogenous levels. Using a FLAG antibody, we pulled-down Epe1 and detected its interaction with Swi6^HP1^ using a primary antibody. Swi6^HP1^ is enriched in pull-down experiments in wild-type cells relative to an untagged control ([Figure 2A](#fig2){ref-type="fig"}). However, mutations in residues that affect Fe(II) or α-ketoglutarate binding (H297A, Y307A, and Y370A) significantly attenuate this interaction ([Figure 2A](#fig2){ref-type="fig"}). Altering the position of the FLAG epitope tag did not alter the conclusions of our experiments. Epe1 fused to an N-terminal FLAG tag interacts with Swi6^HP1^, whereas a mutation within the JmjC domain (H297A) compromises its binding ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}).

![Mutations within the JmjC domain perturb a direct interaction between Epe1 and Swi6^HP1^.\
(**A**) Western blots of co-immunoprecipitation (co-IP) measurements to test the interaction between Epe1-3XFLAG and Swi6^HP1^. Epe1 is detected using a FLAG antibody and Swi6^HP1^ is detected using a primary antibody. The interaction between the two proteins is preserved in wild-type cells and is completely eliminated in all Epe1 JmjC mutants. (**B**) ChIP-qPCR measurements of Epe1 occupancy at sites of constitutive heterochromatin (*dg* pericentromeric repeats) (N = 2). Error bars represent standard deviations. Epe1 enrichment is reduced to near background levels (*swi6Δ* and *clr4Δ*) in loss of function mutants of Epe1. (**C**) Western blots of in vitro binding assays using recombinant Epe1 protein. Increasing amounts of wild-type MBP-Epe1 protein are added while maintaining a fixed amount of 3X-FLAG-Swi6^HP1^ or 3X-FLAG-Chp2 ^HP1^ on beads. Epe1 exhibits a binding preference for Swi6^HP1^over Chp2 ^HP1^. (**D**) Increasing amounts of wild-type MBP-Epe1 protein are added while maintaining a fixed amount of 3X-FLAG- Swi6^HP1^ or a CSD domain mutant, 3X-FLAG Swi6^HP1^ L315E on beads. Western blots revealed that a point mutation in the conserved Swi6 ^HP1^CSD domain (L315E) leads to reduced levels of interaction between recombinant Epe1 and Swi6^HP1^ L315E. (**E**) Increasing amounts of wild-type MBP-Epe1 and MBP-Epe1 H297A are added while maintaining a fixed amount of 3XFLAG- Swi6^HP1^ on beads. Experiments were performed in the presence and absence of EDTA to measure co-factor independent interactions between the two proteins. The binding recombinant Epe1 H297A binding to Swi6^HP1^ is significantly reduced relative to the wild-type protein.](elife-53155-fig2){#fig2}

Epe1 is enriched at sites of constitutive heterochromatin, which include the pericentromeric *dg* and *dh* repeats, the mating type locus, and the telomeres ([@bib63]). We used formaldehyde to crosslink cells followed by chromatin immunoprecipitation to compare heterochromatin occupancy differences between Epe1 wild-type and Epe1 co-factor binding mutants. After crosslinking, we used a FLAG antibody to pull-down the chromatin-bound fraction of Epe1. We used qPCR to measure Epe1 occupancy at the pericentromeric *dg* repeats. Epe1 is enriched within *dg* repeats in wild-type cells and this heterochromatin-specific occupancy pattern is disrupted both in *swi6Δ* and *clr4Δ* cells ([Figure 2B](#fig2){ref-type="fig"}). Mutations within the JmjC domain that disrupt co-factor binding lead to a substantial reduction in Epe1 occupancy at sites of heterochromatin formation. Consistent with our co-immunoprecipitation studies, all co-factor binding mutants of Epe1 exhibit a significant reduction or completely fail to localize at the pericentromeric *dg* repeats ([Figure 2B](#fig2){ref-type="fig"}). We altered our fixation conditions using additional reactive crosslinkers and extended the time for formaldehyde crosslinking. Altering crosslinking conditions did not lead to a significant increase in chromatin occupancy amongst Epe1 mutants ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Based on these results, we concluded that Epe1 co-factor binding mutants exhibit significant defects in their ability to interact with Swi6^HP1^ and a complete inability to localize at sites of heterochromatin formation.

Our co-immunoprecipitation, imaging, and ChIP experiments preclude us from making any conclusions as to whether the interaction between Epe1 and Swi6^HP1^ is mutation-dependent or requires the putative catalytic functions of Epe1 in vivo. To address this concern, we purified MBP fusions of wild-type Epe1 and Epe1 H297A from insect cells. Swi6^HP1^ was purified from *E. coli*. We used TEV protease to cleave the MBP tag and confirmed that recombinant Epe1 remains soluble, but preserved the tag in subsequent purifications for our binding assays ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). We compared the thermal stability of the wild-type and mutant Epe1 protein (Epe1 H297A) using isothermal calorimetry measurements ([Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}). Wild-type Epe1 and Epe1 H297A exhibit similar denaturation temperatures, implying that the mutation within the JmjC domain does not destabilize the protein or cause substantial alterations in protein structure. The difference in peak intensities in the isothermal calorimetry (ITC) profile reflects differences in protein amounts in this assay. These results are consistent with structural studies of JmjC domain-containing proteins where the loss of co-factor binding within the active site does not alter protein structure ([@bib23]).

To perform in vitro binding assays, we immobilized Swi6^HP1^ on FLAG beads and added three different concentrations of Epe1. Epe1 was detected in these binding assays using an MBP antibody and the total amount of Swi6^HP1^ was measured using a FLAG antibody. Through a series of titration measurements, we found that using an MBP antibody and a chemiluminescence based readout produces a very limited linear response, which precludes us from reporting an apparent K~d~. We verified that the Epe1 protein we purified from insect cells preferentially interacts with Swi6^HP1^ as opposed to a second HP1 homolog in *S. pombe,* Chp2^HP1^ ([Figure 2C](#fig2){ref-type="fig"}). Hence, the recombinant Epe1 protein we purified from insect cells recapitulates a known binding preference of Epe1 towards Swi6^HP1^ ([@bib43]). The CSD domain of Swi6^HP1^ mediates protein dimerization and regulates Swi6^HP1^-dependent protein-protein interactions ([@bib10]). We expressed and purified a dimerization deficient mutant of Swi6 from *E. coli* (3XFLAG-Swi6^HP1^ L315E). Our binding assays using the mutant Swi6^HP1^ protein (Swi6^HP1^ L315E) reveal a significant reduction in its ability to interact with Epe1 ([Figure 2D](#fig2){ref-type="fig"}). Therefore, Epe1 interacts with Swi6^HP1^ through a conserved mechanism that is shared across other heterochromatin associated factors.

To test whether a mutation within the JmjC domain leads to a loss of interaction between Epe1 and Swi6^HP1^, we compared binding assays between the recombinant wild-type Epe1 protein and the Fe (II) binding deficient mutant, Epe1 H297A. Adding increasing quantities of the wild-type MBP-Epe1 leads to a corresponding increase in the amount of protein that interacts with Swi6^HP1^. However, this type of interaction and increase in binding is not observed in the case of MBP-Epe1 H297A ([Figure 2E](#fig2){ref-type="fig"}). We compared binding assays performed in the presence and absence of EDTA to rule out any potential contributions that may arise from divalent metals ions that bind to the JmjC domain. The interaction between Epe1 and Swi6^HP1^ is nearly identical in the presence or absence of EDTA ([Figure 2E](#fig2){ref-type="fig"}). These results suggest that the interaction between Epe1 and Swi6^HP1^ is direct but disrupted by mutations that map to the putative catalytic JmjC domain.

To test whether the enzymatic activity of Epe1 may enhance its interaction with Swi6^HP1^, we added Fe (II), α-ketoglutarate and ascorbate to mimic 'histone-demethylase reaction conditions' in our in vitro binding assays ([@bib53]). The addition of co-factors required for histone demethylation did not alter the extent of interaction between Epe1 and Swi6^HP1^ ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}). Hence, our in vitro assays fail to capture any effect that co-factor binding itself may have on the interaction between Epe1 and Swi6^HP1^. We also tested whether the interaction between *S. pombe* Swi6^HP1^ and Epe1 might be different from the data we obtained using Swi6^HP1^ purified from *E. coli* ([Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}). Swi6^HP1^ phosphorylation remains intact during our purification as indicated by an upward mobility shift in *S. pombe* Swi6^HP1^ compared to *E. coli* Swi6^HP1^ ([Figure 2---figure supplement 1G](#fig2s1){ref-type="fig"}). However, we observed no differences in the interaction profile with Epe1 suggesting that the loss of binding we detected in the Epe1 H297A mutant is independent of Swi6^HP1^ post-translational modifications ([@bib45]). These results suggest that mutations within the JmjC domain of Epe1 may induce a conformational change that attenuates Swi6^HP1^ binding ([@bib48]).

Next, we tested whether Swi6^HP1^ binding to Epe1 may activate its latent enzymatic properties. We performed histone demethylase assays using recombinant Epe1 in the presence and absence of Swi6^HP1^. We used histone H3 tail peptides with a di-methyl or a tri-methyl modification at the lysine nine position (H3K9me2 or H3K9me3 peptides) as substrates. We were unable to detect a mass shift corresponding to the removal of one or more methyl groups in reactions that we performed with Epe1 alone or Epe1 in complex with a five-fold molar excess of Swi6^HP1^ ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). In contrast, JMJD2A, an active demethylase, is fully capable of demethylating an H3K9me3 peptide substrate ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}). Hence, Swi6^HP1^ binding to Epe1 is not sufficient to activate its putative enzymatic functions.

Swi6^HP1^ interacts with the C-terminus of Epe1 through a region that is proximal to the JmjC domain {#s2-3}
----------------------------------------------------------------------------------------------------

To map the Swi6^HP1^ interaction site within Epe1, we used an in vitro translation (IVT) assay where we expressed fragments of Epe1 and tested their ability to interact with Swi6^HP1^. We used a computational disorder prediction program to define ordered and disordered regions within the protein ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). The JmjC domain emerges as one of two ordered regions extending from amino acids 233--434. The second ordered domain that is located within the C-terminus of the protein has no known similarity to existing protein structures and does not have any ascribed function. We designed and expressed partial fragments of Epe1 using rabbit reticulocyte lysates including the full-length protein as a positive control. We added FLAG beads that were pre-incubated with 3XFLAG-Swi6^HP1^ to the IVT extract. A C-terminal fragment of Epe1 spanning 434--948 amino acids and an N-terminal fragment of Epe1 encompassing 1--600 amino acids (Epe1-ΔC) emerged as putative Swi6^HP1^ interaction candidates ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). We hypothesized that the binding region would lie somewhere between amino acid positions 434 and 600. Importantly, this region is proximal to but non-overlapping with the predicted JmjC domain of Epe1.

To validate the conclusions of our IVT binding assay, we expressed and purified two C-terminal fragments of Epe1 from *E. coli.* The first fragment encompasses the entire C-terminus of Epe1 from 434 to 948 amino acids (Epe1^434-948^). The second fragment corresponds to only the minimal Swi6^HP1^ interaction site extending from 434 to 600 amino acids (Epe1^434-600^). We performed binding assays comparing the interaction between the full-length Epe1 protein and the Epe1 C-terminal fragment (Epe1^434-948^) with Swi6^HP1^. The Epe1 C-terminal fragment exhibits an increase in its interaction with Swi6^HP1^ relative to full-length Epe1 ([Figure 3A](#fig3){ref-type="fig"}). Hence, the C-terminal domain of Epe1, when placed in the context of the full-length protein, is less accessible to Swi6^HP1^. We obtained similar results when we tested the interaction between Epe1^434-600^ and Swi6^HP1^ ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). These observations raise the possibility that the JmjC domain has a steric function and its presence in the context of the full-length protein may impede Swi6^HP1^ binding. We also performed co-immunoprecipitation experiments in cells expressing 3XFLAG-Epe1^434-948^ and detected the same pattern of interaction with Swi6^HP1^ as measured in our in vitro assay ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). We noted that the expression level of the 3X FLAG-Epe1^434-948^ protein expressed from the endogenous *epe1* locus is at least four-fold lower compared to the full-length protein ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}).

![Swi6^HP1^ interacts with the C-terminus of Epe1 through a region that is proximal to the JmjC domain.\
(**A**) Western blots of in vitro binding assays to validate the interaction between Swi6^HP1^ and the Epe1 C-terminus. Increasing amounts of MBP-Epe1^434-948^ protein are added while maintaining a fixed amount of 3X-FLAG-Swi6^HP1 ^on beads. MBP-Epe1^434-948^ exhibits an increase in its interaction with Swi6 ^HP1^ compared to full-length Epe1. (**B**) Western blots of an in vitro binding assay between FLAG-Epe1-N (1--434 amino acids) purified from *S. pombe* and recombinant MBP-Epe1^434-948^ in the presence and absence of recombinant Swi6^HP1^. The addition of Swi6^HP1^ disrupts a direct *trans* interaction between the N- and C-terminal halves of Epe1. The asterisk in the figure denotes the non-specific FLAG antibody band. (**C**) Phenotype assays of epigenetic inheritance as a measure of Epe1 activity. Cells expressing Epe1^434-948^ were plated on −tetracycline and +tetracycline medium. Cells are initially red during establishment. Despite the absence of the putative catalytic JmjC domain, cells expressing Epe1^434-948^ partly turn white on +tetracycline medium. (**D**) Quantification of red or sectored colonies comparing *epe1Δ* and Epe1^434-948^ expressing cells. Epe1^434-948^ expressing cells have 30% fewer sectored colonies compared to *epe1Δ* cells. (**E**) A dominant interaction between the Epe1 C-terminus and Swi6^HP1^ opposes heterochromatin establishment. TetR-Swi6-CSD was expressed in cells that harbor *10X TetO* binding sites upstream of an *ade6^+^* reporter gene. The expression of the Epe1 C-terminus alone in the absence of its putative catalytic JmjC domain disrupts heterochromatin establishment causing cells to remain white under --tetracycline and +tetracycline conditions. (**F**) ChIP-qPCR measurements of H3K9me2 levels at the ectopic site (*10X tetO ade6+*) during establishment (−tetracycline) in a wild-type, *epe1Δ* and two independent clones expressing Epe1^434-948^ (N = 2). Error bars represent standard deviations. (**G**) ChIP-qPCR measurements of H3K9me2 levels at the ectopic site (*10X tetO ade6+*) during maintenance (+tetracycline) in wild-type, *epe1Δ* and two independent clones expressing Epe1^434-948^ (N = 2). Error bars represent standard deviations.](elife-53155-fig3){#fig3}

Although the Swi6^HP1^ binding site lies outside the confines of the JmjC domain of Epe1, point mutations within the putative catalytic JmjC domain perturb a direct interaction between the two proteins ([Figure 2A](#fig2){ref-type="fig"}). We hypothesized the existence of an interaction in *cis* where the N-terminus half of the protein (Epe1-N, 1--434 amino acids) interacts with its C-terminal portion (Epe1-C, 434--948 amino acids) to interrupt Swi6^HP1^ binding. To test this model, we expressed and purified the N-terminal half of Epe1 containing the JmjC domain (1--434 amino acids) fused to a 3X-FLAG epitope tag in fission yeast cells (3XFLAG-Epe1-N). The purified protein was retained on beads without elution and immediately used for subsequent binding assays. *S. pombe* cells express limiting amounts of the Epe1 N-terminal fragment, which are sufficient for the binding assays described here. We subsequently added a defined amount of the recombinant C-terminal Epe1 fragment (MBP-Epe1^434-948^). We detected a direct interaction between the Epe1-N and Epe1-C terminal fragments ([Figure 3B](#fig3){ref-type="fig"}, lane 1). Next, we supplemented our binding assays with a two-fold molar excess of recombinant Swi6^HP1^ relative to MBP-Epe1^434-948^. The addition of recombinant Swi6^HP1^ is sufficient to compete with and disrupt a *trans* interaction between the Epe1-N and Epe1-C fragments ([Figure 3B](#fig3){ref-type="fig"}, lane 2).

We also performed experiments where we used lysates derived from *swi6+* or *swi6Δ* cells expressing an Epe1-N fragment (wild-type or Fe (II) binding mutant allele, Epe1 H297A). We incubated these lysates with a recombinant C-terminal Epe1 fragment, MBP-Epe1^434-948^ immobilized on an amylose resin. Compared to bead-only controls where the amylose resin was incubated with cell lysates, we discovered that the C-terminal Epe1 fragment, MBP-Epe1^434-948^ is able to interact with and pull-down Epe1-N (1-434) in *trans* from a complex mixture of proteins ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). We also observed this *trans* interaction in lysates derived from *swi6Δ* cells further supporting the notion that the interaction between the N and C terminal halves of Epe1 is direct and not mediated by Swi6^HP1^ ([Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}).

One prediction emerging from our biochemical analyses is that expressing the Epe1 C-terminus (Epe1^434-948^) alone might oppose heterochromatin assembly through its direct interaction with Swi6^HP1^. As previously described, we used a reporter gene assay where a TetR-Clr4-I fusion protein initiates heterochromatin establishment in an inducible manner. We expressed Epe1^434-948^ protein in this reporter strain. Surprisingly, this mutant protein, which completely lacks the JmjC domain, can reverse epigenetic maintenance. This reversal leads to a greater proportion of cells that turn white upon +tetracycline addition ([Figure 3C](#fig3){ref-type="fig"}). The expression of the Epe1 C-terminal fragment, Epe1^434-948^ results in a phenotype that is substantially different compared to Epe1 co-factor binding mutants or *epe1Δ* cells. We quantified the number of red or sectored colonies in the Epe1 JmjCΔ mutant compared to *epe1Δ* and wild-type cells. Cells that express a full-length wild-type copy of Epe1 turn white on +tetracycline medium and show no trace of red, pink, or sectored colonies. We observed a three-fold reduction in the number of red or sectored colonies in the Epe1 JmjCΔ mutant compared to Epe1 null cells ([Figure 3D](#fig3){ref-type="fig"}). Therefore, the Epe1^434-948^ mutant is a hypomorphic allele that partially retains wild-type levels of Epe1 anti-silencing activity.

The non-enzymatic function of Epe1 revolves around its dominant mode of interaction with Swi6^HP1^. Therefore, we devised a new ectopic silencing approach where the TetR DNA binding protein was fused to the CSD domain of Swi6^HP1^. We hypothesized that the ability of Epe1 to impede heterochromatin establishment might be more pronounced in this reporter strain. We expressed TetR-Swi6-CSD protein in cells where 10X *TetO* repeats were placed upstream of an *ade6+* reporter. Tethering TetR-Swi6-CSD in wild-type cells fails to establish epigenetic silencing. Cells remain white in the presence or absence of +tetracycline ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). We discovered that Epe1 is the rate-limiting factor that prevents heterochromatin establishment in this ectopic paradigm. Cells turn red and establish epigenetic silencing upon deleting *epe1Δ.* Furthermore, cells remain red even after the addition of +tetracycline consistent with robust sequence-independent epigenetic inheritance in this mutant background ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). Next, we expressed only the C-terminal fragment of Epe1 (Epe1^434-948^). Remarkably, this C-terminal fragment, which is devoid of the JmjC domain, completely blocks heterochromatin establishment. Cells remain white in the presence or absence of +tetracycline ([Figure 3E](#fig3){ref-type="fig"}). We occasionally observed clonal populations that exhibit red colonies (25% of transformants) consistent with the notion that other domains within Epe1 exert additional enzymatic or non-enzymatic functions ([@bib8]; [@bib48]). To test whether the phenotypes we observed depend on H3K9 methylation, we used chromatin immunoprecipitation assays followed by qPCR to measure H3K9me2 levels associated with the *ade6+* reporter gene before and after tetracycline addition. H3K9me2 was observed in cells that turned red in an *epe1Δ* background in the presence or absence of tetracycline ([Figure 3F, G](#fig3){ref-type="fig"}). Wild-type cells and cells expressing the Epe1-C fragment fail to exhibit any significant enrichment in H3K9me2. In addition, *epe1Δ clr4Δ* cells exhibit a complete loss of epigenetic silencing, further supporting our observations that H3K9 methylation has a causal role in TetR-Swi6-CSD initiated silencing ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}).

H3K9 methylation stimulates complex formation between Epe1 and Swi6^HP1^ {#s2-4}
------------------------------------------------------------------------

We speculated that a heterochromatin-specific trigger might regulate the interaction between the N- and C-terminus of Epe1 to stabilize its interaction with Swi6^HP1^. We expressed Epe1 fused to a 3XFLAG epitope tag in cells that lack the H3K9 methyltransferase, Clr4^Suv39h^ or strains where the wild-type H3 allele is replaced with an H3K9R mutant. We performed a co-immunoprecipitation assay where we pull-down Epe1 with a FLAG antibody and measured its interaction with Swi6^HP1^. Although Epe1 interacts with Swi6^HP1^ in wild-type cells, this interaction is obliterated in both of the H3K9 methylation deficient mutant strains, *clr4Δ* and H3K9R mutants ([Figure 4A](#fig4){ref-type="fig"}). Furthermore, deleting histone deacetylases Sir2 or Clr3, both of which affect heterochromatin formation and Swi6^HP1^ localization, also resulted in a substantial decrease in the interaction between Epe1 and Swi6^HP1^ ([Figure 4B](#fig4){ref-type="fig"}). In contrast, deleting Mst2, a histone acetyltransferase that enhances heterochromatin formation leads to no change in the interaction pattern between Epe1 and Swi6^HP1^ ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}; [@bib42]). Hence, our results indicate that H3K9 methylation and functional heterochromatin are pre-requisites for complex formation between Epe1 and Swi6^HP1^ in cells.

![H3K9 methylation stimulates complex formation between Epe1 and Swi6^HP1^.\
(**A**) Western blots of co-immunoprecipitation measurements reveal an interaction between Epe1-3XFLAG and Swi6^HP1^ in the case of wild-type cells, which is completely absent in H3K9 methylation deficient cells (*clr4Δ* and H3K9R). (**B**) Co-immunoprecipitation measurements reveal that deletion of histone deacetylases Clr3 or Sir2 which disrupt heterochromatin formation, also leads to a concomitant loss in the interaction between Epe1-3XFLAG and Swi6 ^HP1^. (**C**) Western blots of in vitro binding assays between recombinant Epe1 and Swi6 ^HP1^ in the presence of histone H3 tail peptides (1--15 amino acids). Increasing amounts of wild-type MBP-Epe1 are added while maintaining a fixed amount of 3XFLAG- Swi6^HP1^ on beads. Experiments were performed in the presence of an unmethylated H3 peptide (H3K9me0) (lanes 4--6) or an H3K9 tri-methylated peptide (H3K9me3) (lanes 7--9). Epe1 exhibits a significant increase in its ability to interact with Swi6^HP1^ in the presence of an H3K9me3 peptide. (**D**) Western blots of in vitro binding assays between recombinant Epe1 and Swi6^HP1^ in the presence of differentially methylated histone H3 tail peptides (1--15 or 1--21 amino acids). Increasing amounts of wild-type MBP-Epe1 are added while maintaining a fixed amount of 3XFLAG-Swi6^HP1^ on beads. Experiments were performed in the presence of an unmethylated H3 peptide (H3K9me0), an H3K9 tri-methylated peptide (H3K9me3), or an H3K4 tri-methylated peptide (H3K4me3). Epe1 exhibits a significant increase in its ability to interact with Swi6^HP1^ in the presence of an H3K9me3 but not an H3K4me3 peptide. (**E**) Western blots of in vitro binding assays between recombinant Epe1 and Swi6^HP1^ W104A in the presence of histone H3 tail peptides (1--15 or 1--21 amino acids). Increasing amounts of wild-type MBP-Epe1 are added while maintaining a fixed amount of 3XFLAG- Swi6^HP1^ W104A on beads. Experiments were performed in the presence of an unmethylated H3 peptide (H3K9me0) or an H3K9 tri-methylated peptide (H3K9me3). Epe1 exhibits an increase in its ability to interact with Swi6^HP1^ W104A in the presence of an H3K9me3 peptide.](elife-53155-fig4){#fig4}

We reconstituted a requirement for H3K9 methylation in stabilizing the interaction between Epe1 and Swi6^HP1^ using binding assays as previously described. We supplemented our in vitro binding assays with an unmethylated histone H3 peptide (H3K9me0, H3 1--15 amino acids) or an H3K9 tri-methylated peptide (H3K9me3, H3 1--15 amino acids). Compared to reactions where no-peptide (lanes 1--3) or an unmethylated H3 peptide was added (lanes 4--6), we observed a substantial increase in the interaction between Epe1 and Swi6^HP1^ specifically in the presence of an H3K9me3 peptide (lanes 7--9) ([Figure 4C](#fig4){ref-type="fig"}). An H3K9me2 peptide was also capable of stimulating the interaction between Epe1 and Swi6^HP1^ compared to reactions where no peptide was added or assays where an unmodified peptide was used ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). To test whether the stimulation in the interaction between Epe1 and Swi6^HP1^ is specific to H3K9 methylation, we carried out binding assays in the presence of an H3K4 tri-methylated peptide (H3K4me3). The addition of an H3K4me3 peptide fails to enhance complex formation between Epe1 and Swi6^HP1^, unlike the significant enhancement in binding we observed upon addition of an H3K9me3 peptide ([Figure 4D](#fig4){ref-type="fig"}). Hence, the stimulatory effect we observed in our binding assays is specific to either H3K9me2 or H3K9me3 peptides.

Our previous results reveal a severe reduction in the interaction between Epe1 H297A and Swi6^HP1^ compared to wild-type Epe1 ([Figure 2E](#fig2){ref-type="fig"}). We compared binding assays between MBP-Epe1 and MBP-Epe1 H297A with Swi6^HP1^ in the presence of an H3K9me3 peptide or an H3K9me0 peptide. Although we observed a strong stimulation in the interaction between wild-type Epe1 and Swi6^HP1^ (compare lanes 1--3 with 7--9), this stimulatory effect was significantly reduced in the Epe1 H297A mutant (compare lanes 4--6 with 10--12) ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). These results suggest that the JmjC mutant of Epe1 remains refractory to any interaction with Swi6^HP1^ in the presence or absence of H3K9 methylation.

One possibility is that Swi6^HP1^ undergoes a conformational change that reverses auto-inhibition upon interaction with an H3K9me3 peptide ([@bib10]). To test this hypothesis, we purified a chromodomain mutant Swi6^HP1^ protein from *E. coli.* A tryptophan to alanine substitution (W104A) within the Swi6^HP1^ chromodomain causes a significant reduction in H3K9 methylation binding ([@bib27]). We used peptide binding assays to confirm that the Swi6^HP1^ W104A mutant indeed exhibits a substantial defect in H3K9me3 peptide binding in comparison to the intact Swi6^HP1^ protein ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). We tested whether Swi6^HP1^ W104A protein binding to Epe1 can also be stimulated in the presence of an H3K9me3 peptide. We added increasing amounts of MBP-Epe1 while maintaining a fixed amount of 3X-FLAG Swi6^HP1^ (W104A) on beads. Despite Swi6^HP1^ being unable to bind to an H3K9me3 tail peptide, we observed a stimulation in the interaction between Epe1 and the Swi6^HP1^ (W104A) ([Figure 4E](#fig4){ref-type="fig"}).

In addition, we purified a Swi6^HP1^ Loop-X mutant that abolishes auto-inhibition and prevents chromodomain-dependent dimerization ([@bib10]). We tested whether the wild-type Epe1 protein and a Swi6^HP1^ Loop-X mutant that is constitutively released from auto-inhibition is sensitive to the presence of an H3K9me3 peptide. We purified 3X-FLAG Swi6^HP1^ Loop-X mutant from *E. coli* and immobilized the protein on FLAG beads. We added increasing amounts of Epe1 in the presence of an H3K9me0 or an H3K9me3 peptide. Although the H3K9me0 peptide has no effect on the interaction between Epe1 and Swi6^HP1^ Loop-X, the presence of an H3K9me3 peptide substantially enhances their interaction. Therefore, Epe1 remains responsive to the presence of an H3K9 methylated peptide even in a context where Swi6^HP1^ is constitutively released from auto-inhibition ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}).

An Epe1 C-terminal truncation mutant exhibits enhanced binding to Swi6^HP1^ and is insensitive to H3K9 methylation {#s2-5}
------------------------------------------------------------------------------------------------------------------

Our previous results suggest that Epe1 might have a latent capacity to bind to H3K9 methylated peptides or histones. We tested whether Epe1 directly binds to an H3K9me3 peptide and specifically interacts with H3K9 methylated histones. We performed peptide binding assays where a biotinylated H3K9me3 peptide was immobilized on streptavidin beads. Our binding assays detect a direct interaction between Epe1 and an H3K9me3 peptide as opposed to an unmodified H3K9me0 peptide. Furthermore, Epe1 selectively interacts with H3K9 methylated histones as opposed to H3K4 methylated histones. ([Figure 5A,B](#fig5){ref-type="fig"}). Next, we expressed and purified a C-terminal truncation mutant of Epe1, MBP-Epe1-ΔC from Sf9 insect cells, which includes amino acids 1--600 and includes the putative catalytic JmjC domain. We found that Epe1-ΔC can also directly bind to an H3K9me3 peptide and specifically interacts with H3K9 methylated histones ([Figure 5---figure supplement 1A,B](#fig5s1){ref-type="fig"}). Based on these observations, we hypothesize that the JmjC domain of Epe1 (amino acids 233--434) might be primarily responsible for H3K9 methylation recognition and binding.

![An Epe1 C-terminal truncation mutant exhibits enhanced binding to Swi6 and is insensitive to H3K9 methylation.\
(**A**) Biotinylated peptides (H3K9me3 or H3K9me0) are immobilized on streptavidin beads and incubated with MBP-Epe1. MBP-Epe1 preferentially associates with an H3K9me3 peptide compared to an H3K9me0 peptide. (**B**) Epe1 specifically interacts with H3K9me3 histones. Calf-thymus histones containing an unspecified mixture of differentially modified histones were incubated with MBP-Epe1 immobilized on an amylose resin. Epe1 preferentially interacts with H3K9 methylated histones as opposed to H3K4 methylated histones. (**C**) Western blots of an in vitro binding assay to determine whether an H3K9me3 peptide disrupts a *trans* interaction between the N- and C-terminal halves of Epe1. The N-terminus of Epe1, 3X FLAG-Epe1-N (1-434) was purified using a FLAG antibody from fission yeast cells. The purified protein was incubated with recombinant MBP-Epe1^434-948^ protein in the presence of an H3K9me0 peptide and an H3K9me3 peptide. The H3K9me3 peptide specifically disrupts a direct *trans* interaction between the N- and C-terminal halves of Epe1. (**D**) Western blots of in vitro binding assays comparing the interactions between recombinant Epe1-ΔC and Swi6^HP1^. Increasing amounts of wild-type MBP-Epe1 or MBP-Epe1-ΔC are added while maintaining a fixed amount of 3XFLAG- Swi6^HP1^ on beads. Epe1-ΔC (lanes 4--6) clearly surpasses the full-length protein (lanes 1--3) in terms of its ability to interact with Swi6^HP1^. (**E**) Western blots of in vitro binding assays between recombinant Epe1-ΔC and Swi6 ^HP1^ in the presence of histone H3 tail peptides (1--15 amino acids). Increasing amounts of MBP-Epe1-ΔC are added while maintaining a fixed amount of 3XFLAG-Swi6^HP1^ on beads. Experiments were performed in the presence of an unmethylated H3 peptide (H3K9me0) (lanes 1--3) or an H3K9 tri-methylated peptide (H3K9me3) (lanes 4--6). Epe1-ΔC exhibits no change in its interaction with Swi6^HP1^ in the presence of an H3K9me3 peptide.](elife-53155-fig5){#fig5}

We previously demonstrated that the addition of Swi6^HP1^ disrupts an interaction in *trans* between the Epe1-N and Epe1-C terminus ([Figure 3B](#fig3){ref-type="fig"}). The stimulation in Swi6^HP1^ binding that we observed prompted us to test whether Epe1 binding to an H3K9 methylated peptide might also have a similar function and interrupt a *trans* interaction between the Epe1 N- and C- terminal fragments. Disrupting their interaction would enable Swi6^HP1^ to gain access to the C-terminus of Epe1. To test this model, we measured a *trans* interaction between the Epe1 N- and C-terminal halves in the presence of an H3K9me0 peptide or an H3K9me3 peptide ([Figure 5C](#fig5){ref-type="fig"}). We purified an Epe1-N fragment fused to a 3X FLAG epitope tag. Next, we added a recombinant Epe1 C-terminal fragment (434--948 amino acids) in the presence of an H3K9me0 peptide or an H3K9me3 peptide. We observed an interaction in *trans* between the N- and C-terminal halves of Epe1 in binding assays with no peptide or an H3K9me0 peptide. However, the addition of an H3K9me3 peptide eliminates the interaction between the N- and C-terminal fragments of Epe1 ([Figure 5C](#fig5){ref-type="fig"}).

Based on our observations, we hypothesized that the C-terminus of Epe1 might have a regulatory function in enforcing an H3K9 methylation-dependent mode of interaction between Epe1 and Swi6^HP1^. To test this model, we expressed a C-terminal truncation of Epe1 (Epe1-ΔC) fused to a 3XFLAG epitope tag in fission yeast cells. We performed a co-IP experiment to test the interaction between Epe1-ΔC, and Swi6^HP1^ compared to the full-length protein. We also expressed an N-terminal fragment of Epe1 (Epe1-N) which lacks the Swi6^HP1^ binding site. Our co-IP assays detect a substantial increase in the interaction between Epe1-ΔC and Swi6^HP1^, compared to a weak interaction in the case of the full-length protein and no interaction in the case of Epe1-N ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Next, we performed in vitro binding assays to test the extent of interaction between recombinant MBP-Epe1-ΔC and FLAG-Swi6^HP1^ relative to the full-length Epe1 protein. Epe1-ΔC significantly outperforms the full-length protein in its ability to interact with Swi6^HP1^ (compare lanes 4--6 with lanes 1--3) ([Figure 5D](#fig5){ref-type="fig"}).

We performed binding assays where we added increasing amounts of Epe1-ΔC while maintaining a fixed concentration of Swi6^HP1^ on beads in the presence of an H3K9me0 or an H3K9me3 peptide. Surprisingly, the addition of a modified peptide had no effect on the interaction between Swi6^HP1^ and Epe1-ΔC ([Figure 5E](#fig5){ref-type="fig"}). This is not because of saturation of the chemiluminescent signal as the addition of increasing amounts of Epe1-ΔC continues to produce a concomitant increase in its interaction with Swi6^HP1^. Previously, we demonstrated that the interaction between full-length Epe1 and Swi6^HP1^ requires functional heterochromatin. We performed a co-IP measurement in *clr4+* and *clr4Δ* cells expressing FLAG-Epe1-ΔC. Consistent with our in vitro binding assays and unlike the full-length Epe1 protein, we observed an interaction between Epe1-ΔC and Swi6^HP1^ in both *clr4+* and *clr4Δ* cells ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). Therefore, Epe1-ΔC remains unresponsive to the presence of H3K9 methylation and does not undergo any further stimulation in its ability to interact with Swi6^HP1^.

Epe1 inhibits Swi6-dependent heterochromatin assembly through a non-enzymatic process {#s2-6}
-------------------------------------------------------------------------------------

We hypothesized that Epe1 might outcompete other heterochromatin associated proteins that localize to sites of heterochromatin formation through a dominant interaction with Swi6^HP1^. Genetic studies reveal that Epe1 and a histone deacetylase Clr3 have opposing effects on nucleosome turnover ([@bib4]). One possibility is that the interaction between Epe1 and Swi6^HP1^ excludes heterochromatin agonists, such as Clr3 from sites of heterochromatin formation. We used a co-immunoprecipitation assay to measure the extent of interaction between Clr3 and Swi6^HP1^. Clr3 was fused to a 3X V5 epitope tag and expressed in a wild-type Epe1 and an Epe1 H297A background. We used a V5 antibody to pull-down Clr3 , after which we detected Swi6^HP1^ using a primary antibody. We measured a weak interaction between Swi6^HP1^ and Clr3 in a wild-type Epe1 background that substantially increases in an Epe1 H297A strain background ([Figure 6A](#fig6){ref-type="fig"}). This positive change in the interaction between Clr3 and Swi6^HP1^ occurs in the absence of any increase in Swi6^HP1^ occupancy at the pericentromeric repeats ([Figure 6B](#fig6){ref-type="fig"}). Although Clr3 is also recruited to sites of heterochromatin formation by interacting with Chp2^HP1^, the levels of Chp2^HP1^ in fission yeast cells are approximately 100-fold lower compared to Swi6^HP1^ ([@bib43]). This difference in stoichiometry between Swi6^HP1^ and Chp2^HP1^ could explain how Epe1 may have an outsized role in interfering with heterochromatin assembly by selectively disrupting Swi6^HP1^ associated protein complexes.

![The interaction between Epe1 and Swi6 displaces Clr3 from localizing to sites of heterochromatin formation.\
(**A**) Epe1 displaces Clr3 from sites of heterochromatin formation. Western blots of a co-immunoprecipitation experiment reveal that Clr3-3X V5 interacts weakly with Swi6^HP1^ in a wild-type Epe1 background. This interaction increases significantly in an Epe1 H297A background. (**B**) ChIP-qPCR measurements of Swi6^HP1^ occupancy at sites of constitutive heterochromatin in wild-type and Epe1 mutant cells. The increase in interaction between Swi6^HP1^ and Clr3 is independent of Swi6^HP1^ levels at constitutive heterochromatin. (**C**) ChIP-qPCR measurements of Epe1 occupancy at *dg* pericentromeric repeats in *clr3Δ* cells (N = 2). Error bars represent standard deviations. Epe1 enrichment is increased two to three-fold in cells at *dg* in *clr3Δ* strains. (**D**) ChIP-qPCR measurements of Epe1 occupancy at the mating-type locus (mat) in *clr3Δ* cells (N = 2). Error bars represent standard deviations. Epe1 enrichment is increased two to three-fold at the *mat locus* in *clr3Δ* strains. (**E**) ChIP-qPCR measurements of Epe1 occupancy at telomeres (*tlh1*) in *clr3Δ* cells (N = 2). Error bars represent standard deviations. Epe1 localization is completely eliminated at the telomeres in *clr3Δ* strains.](elife-53155-fig6){#fig6}

We also measured Epe1 localization in *clr3Δ* mutant cells. Consistent with our model, we observed a three-fold increase in Epe1 localization at the pericentromeric *dg* repeats and the mating type locus (*mat*) ([Figure 6C, D](#fig6){ref-type="fig"}). In contrast, the deletionof *clr3Δ* results in the complete loss of Epe1 localization at the telomeres ([Figure 6E](#fig6){ref-type="fig"}).

We hypothesized that directly tethering Clr3 at an ectopic site would eliminate the requirement for Swi6^HP1^ for its recruitment at sites of heterochromatin formation. In this genetic context, we rationalized that Epe1 would be unlikely to block Clr3 recruitment. One caveat of this experimental strategy is that it does not rule out the possibility that Epe1 and Clr3 have antagonistic catalytic functions. However, this experiment directly tests whether the Clr3 level itself might be rate-limiting at sites of heterochromatin formation. To test this model, we engineered synthetic heterochromatin domains where *10X Tet operator* (*10XTetO*) and *10X Gal4 DNA binding sites* (*10X Gal4*) are placed next to each other and inserted upstream of an *ade6+* reporter gene. This enables inducible heterochromatin formation via TetR-Clr4-I recruitment while the Gal4 DNA binding domain allows for the orthogonal recruitment of additional chromatin effectors to the ectopic site ([Figure 7A](#fig7){ref-type="fig"}). In the absence of any additional chromatin modifiers, TetR-Clr4-I recruitment to the newly engineered ectopic site (*10X Gal4-10X TetO- ade6+*) leads to the appearance of red colonies on --tetracycline medium. Upon the addition of tetracycline, cells turn white consistent with a causal role for Epe1 in resetting epigenetic inheritance ([Figure 1B](#fig1){ref-type="fig"}). We fused the Gal4 DNA binding domain (Gal4 DBD) to two histone deacetylases, Clr3 (a class II histone deacetylase) and Sir2 (a NAD-dependent histone deacetylase) enabling these proteins to be constitutively tethered at the Gal4 DNA binding sites. The TetR-Clr4-I fusion initiates heterochromatin formation and cells turn red on medium lacking tetracycline in the presence of Gal4-Clr3 or Gal4-Sir2 ([Figure 7A](#fig7){ref-type="fig"}). However, upon exposure to tetracycline, the constitutive tethering of Clr3 but not Sir2 promotes epigenetic inheritance. Cells exhibit a red and sectored phenotype in cells where Clr3 is artificially tethered, despite Epe1 still being present ([Figure 7B](#fig7){ref-type="fig"}). The phenotypes in cells where Gal4-Clr3 is tethered are remarkably similar to cells that lack Epe1 (*epe1Δ*). We measured changes in H3K9me2 levels associated with the *ade6+* reporter gene using ChIP-qPCR. Cells maintain high H3K9me2 levels in the presence of Gal4-Clr3 before and after tetracycline ([Figure 7C-D](#fig7){ref-type="fig"}). These results suggest that constitutively tethering Clr3 to sites of heterochromatin formation is sufficient to oppose Epe1 activity resulting in maintenance of H3K9 methylation even after +tetracycline addition.

Tethering Gal4-Clr3 in the absence of TetR-Clr4-I causes no change in reporter gene silencing or H3K9me2 levels at the ectopic site ([Figure 7---figure supplement 1A,B,C](#fig7s1){ref-type="fig"}). Hence, Gal4-Clr3 cannot initiate H3K9 methylation de novo in fission yeast ([Figure 7---figure supplement 1B,C](#fig7s1){ref-type="fig"}). This lack of de novo silencing is consistent with the notion that HDAC proteins in fission yeast collaborate with H3K9 methyltransferases to establish epigenetic silencing. Furthermore, expressing Clr3 minus the Gal4 DBD fusion (Clr3 ΔGal4) leads to a loss of epigenetic maintenance on +tetracycline-containing medium. Therefore, Clr3 must be recruited in *cis* to oppose the anti-silencing effects of Epe1 ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). Consistent with the phenotypes that we observed, H3K9me2 levels are high during establishment but completely absent during maintenance in cells expressing diffusible Clr3 protein ([Figure 7---figure supplement 1B,C](#fig7s1){ref-type="fig"}). Hence, it is the sequence-specific recruitment of Clr3, rather than protein dosage, that facilitates H3K9 methylation maintenance. Therefore, Clr3 recruitment in *cis* is required to maintain silent epigenetic states and oppose Epe1 activity. This property of heterochromatin maintenance is RNAi independent as cells continue to exhibit a red or sectored appearance in a Dicer deficient background (*dcr1Δ*) ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}).

The read-write activity of Clr4^Suv39h^ is essential for the inheritance of silent epigenetic states in a sequence-independent manner ([@bib3]; [@bib40]). This H3K9 methylation-dependent positive feedback loop is disrupted in a Clr4^Suv39h^ chromodomain mutant ([@bib61]). To test whether the chromodomain is essential for maintenance when Clr3 is tethered, we replaced the wild-type allele of Clr4^Suv39^ with a Clr4 mutant that lacks the chromodomain (*clr4ΔCD*). Cells that are initially red in --tetracycline medium turn white on +tetracycline medium in a *clr4ΔCD* expressing mutant ([Figure 7E](#fig7){ref-type="fig"}). H3K9me2 levels in *clr4ΔCD* mutants are similar to those of wild-type cells during establishment. However, H3K9 methylation is absent upon +tetracycline addition in *clr4ΔCD* expressing strains. Hence, the inheritance of H3K9 methylation depends on the read-write activity of Clr4^Suv39h^ despite Clr3 being constitutively tethered ([Figure 7F, G](#fig7){ref-type="fig"}).

![H3K9 methylation regulates the non-enzymatic functions of a putative histone demethylase Epe1, which interacts weakly with Swi6^HP1^.\
(**A**) A reporter system to detect epigenetic inheritance of H3K9 methylation in the presence of orthogonal chromatin effectors. Heterochromatin initiation depends on TetR-Clr4-I binding (-tetracycline). Orthogonal chromatin effectors can be recruited to the *10xgal4* DNA binding site via a Gal4 DNA binding domain (Gal4 DBD). The addition of tetracycline promotes TetR-Clr4-I dissociation to measure epigenetic inheritance in the presence of an orthogonal chromatin effector. (**B**) A color-based assay to detect the establishment and maintenance of epigenetic states. The establishment of epigenetic silencing (-tetracycline) results in red colonies. Tethering Gal4-Clr3 but not Gal4-Sir2 at an ectopic site promotes epigenetic inheritance of H3K9 methylation resulting red or sectored colonies in +tetracycline containing medium in *epe1+* (**C**) ChIP-qPCR measurements of H3K9me2 levels at the ectopic site (*10X tetO ade6+*) during establishment (-tetracycline). (N=2). Error bars represent standard deviations. (**D**) ChIP-qPCR measurements of H3K9me2 levels at the ectopic site (*10X tetO ade6+*) during maintenance (+tetracycline) (N=2). Error bars represent standard deviations. (**E**) The deletion of the Clr4 chromodomain (*clr4ΔCD)* inactivates read-write functions which affects epigenetic inheritance. Cells that are initially red during heterochromatin establishment (-tetracycline) turn white during maintenance (+tetracycline) in a *clr4ΔCD* background. (**F**) ChIP-qPCR measurements of H3K9me2 levels at the ectopic site (*10X tetO ade6+*) during establishment (-tetracycline) in *clr4ΔCD* mutant cells (N=2). Error bars represent standard deviations. ChIP-qPCR values from Figure 7C are plotted as a reference. (**G**) ChIP-qPCR measurements of H3K9me2 levels at the ectopic site (*10X tetO ade6+*) during maintenance (+tetracycline) in *clr4ΔCD* mutant cells (N=2). Error bars represent standard deviations. Error bars represent standard deviations. ChIP-qPCR values from Figure 7D are plotted as a reference.](elife-53155-fig7){#fig7}

Discussion {#s3}
==========

The establishment and maintenance of epigenetic states is primarily thought to depend on a balance of enzymatic activities between readers, writers, and erasers of histone modifications ([@bib2]). However, the replication-dependent and independent turnover of histones serve as a major mechanism that shapes genome-wide patterns of histone methylation ([@bib13]). In *Drosophila*, modified histones are turned over more than once during each cell-cycle , which limits their capacity to serve as carriers of epigenetic information ([@bib14]; [@bib17]; [@bib30]). In principle, passive genome-wide nucleosome exchange can compete with histone modification-dependent read-write mechanisms to oppose epigenetic inheritance.

Our data support the notion that enzymatic erasure is at least in part, dispensable for regulating the inheritance of transcriptionally silent epigenetic states in fission yeast. Our observations are fully consistent with earlier work demonstrating an antagonistic relationship between Epe1, which enhances nucleosome turnover at sites of heterochromatin formation, and Clr3, which suppresses this process ([@bib4]). In addition, Epe1 also has newly defined roles in recruiting members of the SAGA complex which mediate histone acetylation, a chromatin feature that is also associated with increased nucleosome turnover ([@bib8]). Recent work demonstrated a surprising and unexpected function for the N-terminus of Epe1 in transcriptional activation, which suppresses stochastic, epigenetic silencing ([@bib48]). Our findings are complementary to these recent studies and expand the gamut of anti-silencing functions associated with Epe1.

Auto-inhibition is a widely used strategy that proteins use to activate their latent functions in response to specific cellular or environmental signals ([@bib39]). The enzymatic and non-enzymatic properties of proteins can be regulated by internal control mechanisms that act in *cis*. For example, in the case of the chromatin remodeler ALC1, poly ADP ribosylation in response to DNA damage releases the macrodomain of the protein from an auto-inhibited state and activates its latent ATPase-dependent nucleosome remodeling function ([@bib33]; [@bib46]). The non-catalytic heterochromatin associated protein Swi6^HP1^ is auto-inhibited by a histone H3 mimic sequence ([@bib10]). Release from auto-inhibition switches the protein to a spreading competent state.

We discovered that a weak interaction between Epe1 and Swi6^HP1^ can be bolstered by H3K9 methylation. We propose that a *cis* interaction between the N- and C-terminal halves of Epe1 opposes Swi6^HP1^ binding. These results suggest that Epe1 may be preserved in an auto-inhibited state until it interacts with H3K9 methylation ([Figure 8](#fig8){ref-type="fig"}). In the absence of H3K9 methylation, the two proteins fail to form a stable complex in vivo despite their ability to interact directly with each other in vitro. The ability of Epe1 to bind to H3K9 methylation raises the possibility that it competes with Swi6^HP1^ for a shared binding site. However, heterochromatin consists of dense networks of H3K9 methylated nucleosomes. It is also possible that Epe1 while interacting with Swi6^HP1^, can also be stimulated via an interaction with an adjacent or a distal nucleosome. Our data do not lend direct support to a structural change that occurs within Epe1 upon H3K9me3 peptide binding but strongly suggest that modified histones can influence the stability of chromatin associated complexes in living cells.

![H3K9 methylation regulates the non-enzymatic functions of a putative histone demethylase.\
Epe1 interacts weakly with Swi6^HP1^. Point mutations within the catalytic JmjC domain of Epe1 disrupts its interaction with Swi6^HP1^. H3K9 methylation binding stimulates the interaction between Epe1 and Swi6^HP1^ which stabilizes complex formation at sites of heterochromatin formation. The Epe1 C-terminus enforces an H3K9 methylation dependent mode of interaction between Epe1 and Swi6^HP1^ which displaces the histone deacetylase, Clr3 from sites of heterochromatin formation. Our model reveals how H3K9 methylation stabilizes an inhibitory complex consisting of Epe1 and Swi6^HP1^ and suggests how a non-enzymatic function associated with Epe1 C-terminus regulates epigenetic inheritance.](elife-53155-fig8){#fig8}

Swi6^HP1^ is dynamic and undergoes rapid exchange on the millisecond timescale between the free and H3K9 methylation-bound state ([@bib12]; [@bib11]). Given the relative abundance of Swi6^HP1^ in cells, a simple protein-protein interaction between Epe1 and Swi6^HP1^ would effectively titrate Epe1 away from sites of heterochromatin formation. By enforcing an H3K9 methylation-dependent mode of interaction, Epe1 selectively targets a sub-population of Swi6^HP1^ molecules that are bound to sites of H3K9 methylation and have a causal role in heterochromatin formation. Therefore, one outcome of this H3K9 methylation-dependent mode of interaction is that Epe1 selectively interacts with heterochromatin-bound Swi6^HP1^ molecules as opposed to freely diffusing Swi6^HP1^ proteins. It is likely that this balance of protein-protein interactions is tunable via post-translational modifications. For example, Swi6^HP1^ phosphorylation compromises Epe1 binding and promotes histone deacetylase recruitment to sites of heterochromatin formation ([@bib45]). Our studies demonstrate that altering the balance of Swi6^HP1^-dependent protein-protein interactions profoundly affects the stability and heritability of silent epigenetic states.

Tethering Clr3 at an ectopic site renders heterochromatin refractory to the anti-silencing effects of Epe1. Our observations are in part, similar to previous findings relating to the fission yeast mating type locus where DNA binding proteins, Atf1 and Pcr1 recruit Clr3 to maintain epigenetic silencing following an RNAi-dependent initiation mechanism ([@bib58]; [@bib60]). We also recapitulate a unique requirement for the sequence-dependent recruitment of HDAC proteins in *cis* to facilitate the inheritance of silent epigenetic states despite the presence of anti-silencing factors such as Epe1. We favor a model where histone deacetylases such as Clr3 create a chromatin environment that promotes the read-write enzymatic function of Clr4^Suv39h^. In essence, Epe1 prevents Clr3 mediated histone hypoacetylation by forming an inhibitory complex with Swi6^HP1^ within a heterochromatin restricted genomic context.

The question of whether Epe1 harbors any histone demethylase activity remains unanswered. Inspired by earlier studies on the *Drosophila* dKDM4A protein where HP1 binding stimulates demethylase activity, we attempted to reconstitute the enzymatic function of Epe1 in the presence of Swi6^HP1^ ([@bib35]). However, our studies are unable to detect Epe1 mediated enzymatic demethylation in the presence or absence of Swi6^HP1^ ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). It is noteworthy that a histone demethylase like protein in *Neurospora*, DMM-1 shares many similarities with Epe1 and also surprisingly lacks any in vitro enzymatic activity ([@bib22]). DMM-1 also interacts with the HP1 homolog in *Neurospora* leading us to speculate that this surprising mode of heterochromatin regulation we uncovered in the case of Epe1 might also extend to other fungal systems. Given that expressing the C-terminus of Epe1 only partially restores wild-type levels of Epe1 activity ([Figure 3C,D](#fig3){ref-type="fig"}), we speculate that there could potentially be unique substrates or conditions required to reconstitute the enzymatic activity of Epe1. We favor a model in which heterochromatin associated proteins could act as positive or negative allosteric regulators of Epe1. For example, Bdf2, a BRD4 homolog that localizes to heterochromatin boundaries along with Epe1, is a possible candidate that may activate the latent enzymatic functions of Epe1 as H3K9 methylation levels are negligible at the heterochromatin-euchromatin boundary ([@bib56]).

Our observations add to an expanding list of proteins that mimic histone modifiers but have built-in non-enzymatic functions that regulate the establishment and maintenance of epigenetic states. The *Drosophila* protein dKDM4A is a prominent example of a histone demethylase with enzymatic and non-enzymatic functions ([@bib15]). More extreme examples of histone-modifying enzyme mimicry are observed in the case of JARID2, a subunit of the PRC2 complex that shares several characteristics with JmjC domain-containing proteins but has a structural role in regulating PRC2 complex assembly ([@bib29]; [@bib47]). Proteins involved in the *Arabidopsis* RNA-dependent DNA methylation pathway, SUVH2 and SUVH9, resemble SET domain methyltransferases but lack enzymatic activity. Instead, both proteins recognize methylated DNA and are involved in RNA pol V recruitment in plants to establish epigenetic silencing ([@bib28]; [@bib32]). Although Epe1 has a JmjC domain, it is possible that its putative catalytic function has been repurposed to regulate its interaction with Swi6^HP1^. Our data suggest that H3K9 methylation promotes the cooperative assembly of complexes between Epe1 and Swi6^HP1^ at sites of heterochromatin formation.

We speculate that the enzymatic and non-enzymatic functions of Epe1 are likely to oppose heterochromatin assembly on different timescales. As a first approximation, the stabilization of Epe1 at sites of heterochromatin formation is sufficient to displace histone deacetylases and hasten the loss of transcriptional silencing. Hence, the non-enzymatic function of Epe1 serves as the first line of opposition to heterochromatin establishment. This transient inhibition of heterochromatin assembly is likely to be followed by a slower enzymatic step where Epe1 might demethylate H3K9 methylated histones or activate transcription ([@bib48]). Our work provides a biochemical basis for how chromatin associated factors that are thought to purely function as enzymes have non-enzymatic properties that regulate heterochromatin assembly and epigenetic inheritance.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                  Designation                                Source or reference        Identifiers                                                    Additional\
  (species) or resource                                                                                                                                               information
  ------------------------------ ------------------------------------------ -------------------------- -------------------------------------------------------------- --------------------------------------------
  Chemical\                      Trizma base                                Sigma aldrich              Cat\# T1503-5KG                                                
  compound, drug                                                                                                                                                      

  Chemical\                      Boric acid                                 Sigma Aldrich              Cat\# B6768-5KG                                                
  compound, drug                                                                                                                                                      

  Chemical\                      EDTA                                       Sigma Aldrich              Cat\# EDS-500G                                                 
  compound, drug                                                                                                                                                      

  Chemical\                      DTT                                        Thermo Fisher\             Cat\# BP17225                                                  
  compound, drug                                                            Scientific                                                                                

  Chemical\                      HEPES                                      Sigma Aldrich              Cat\# H4034-100G                                               
  compound, drug                                                                                                                                                      

  Chemical\                      Proteinase K                               Thermo Fisher\             Cat\# FEREO0491                                                
  compound, drug                                                            Scientific                                                                                

  Chemical\                      Magnesium chloride\                        Sigma Aldrich              Cat\# M2670-500G                                               
  compound, drug                 hexahydrate                                                                                                                          

  Chemical compound, drug        Potassium chloride                         Sigma Aldrich              Cat\# P9541-500G                                               

  Chemical\                      Sodium chloride                            Thermo Fisher\             Cat\# S271-3                                                   
  compound, drug                                                            Scientific                                                                                

  Chemical compound, drug        Sodium acetate                             Sigma Aldrich              Cat\# S2889-250G                                               

  Chemical\                      Tryptone                                   Thermo Fisher Scientific   Cat\# BP1421-500                                               
  compound, drug                                                                                                                                                      

  Chemical compound, drug        SDS micropellets                           Thermo Fisher\             Cat\# BP8200-500                                               
                                                                            Scientific                                                                                

  Chemical compound, drug        Agarose                                    Thermo Fisher\             Cat\# BP1356-500                                               
                                                                            Scientific                                                                                

  Chemical compound, drug        PMSF                                       Calbiochem                 Cat\# 7110--5 GM                                               

  Chemical compound, drug        Triton X-100                               Sigma Aldrich              Cat\# T8787-250ML                                              

  Chemical compound, drug        Lithium chloride                           Sigma Aldrich              Cat\# L4408-500G                                               

  Chemical compound, drug        Lithium acetate\                           Sigma Aldrich              Cat\# CAS6108-17-4                                             
                                 dihydrate                                                                                                                            

  Chemical\                      Tween 20                                   Thermo Fisher Scientific   Cat\# CAS9005-64-5                                             
  compound, drug                                                                                                                                                      

  Chemical\                      Peptone                                    RPI Research\              Cat\# P20240-1000.0                                            
  compound, drug                                                            Products                                                                                  

  Chemical compound, drug        Leupeptin                                  RPI Research\              Cat\# L22035-0.025                                             
                                                                            Products                                                                                  

  Chemical\                      Aprotinin                                  RPI Research\              Cat\# A20550-0.05                                              
  compound, drug                                                            Products                                                                                  

  Chemical\                      Pepstatin                                  RPI Research Products      Cat\# P30100-0.025                                             
  compound, drug                                                                                                                                                      

  Chemical\                      N-Oxalylglycine                            Sigma Aldrich              Cat\# O9390-10MG                                               
  compound, drug                                                                                                                                                      

  Chemical\                      α-Ketoglutaric acid\                       Sigma Aldrich              Cat\# 75892--25G                                               
  compound, drug                 disodium salt dihydrate                                                                                                              

  Chemical compound, drug        SuperSignal West\                          Thermo Scientific          Cat\# B2162617                                                 
                                 Pico PLUS\                                                                                                                           
                                 Chemiluminescent\                                                                                                                    
                                 Substrate                                                                                                                            

  Chemical compound, drug        Trichloroacetic acid                       Sigma Aldrich              Cat\# T0699-100ML                                              

  Chemical\                      Phenol:chloroform:\                        Sigma Aldrich              Cat\# P3803-100ML                                              
  compound, drug                 isoamyl alcohol                                                                                                                      

  Chemical compound, drug        L-ascorbic acid                            Fisher Chemical            Cat\# C6H8O6                                                   

  Chemical\                      Coblat(II) chloride\                       Sigma Aldrich              Cat\# 255599--100G                                             
  compound, drug                 hexahydrate                                                                                                                          

  Chemical\                      Ammonium iron (II)\                        ACROS ORGANICS             Cat\# 423721000                                                
  compound, drug                 sulfate hexahydrate                                                                                                                  

  Chemical compound, drug        Formaldehyde                               Sigma Aldrich              Cat\# 252549--500 ML                                           

  Chemical\                      Acetonitrile                               OmniSolv                   Cat\# AX0156-1                                                 
  compound, drug                                                                                                                                                      

  Chemical\                      Trifluoroacetic acid                       Fisher Chemical            Cat\# A116−10 × 1 AMP                                          
  compound, drug                                                                                                                                                      

  Chemical compound, drug        Dimethyl pimelimidate                      Thermo Scientific          Cat\# 21667                                                    

  Chemical compound, drug        Ammonium hydroxide solution                Sigma Aldrich              Cat\# 221-228-100ML-A                                          

  Chemical compound, drug        Ethanolamine                               Sigma Aldrich              Cat\# 411000--100 ML                                           

  Chemical\                      Ethyleneglycol bis succinimidylsuccinate   Thermo Scientific          Cat\# 21565                                                    
  compound, drug                                                                                                                                                      

  Chemical compound, drug        Glycogen                                   Sigma Aldrich              Cat\# 10901393001                                              

  Chemical compound, drug        GelGreen Nucleic Acid Stain                BioTium                    Cat\# 41004                                                    

  Chemical\                      30% Acrylamide/\                           Bio-Rad                    Cat\# 1610158                                                  
  compound, drug                 Bis solution, 37.5:1                                                                                                                 

  Chemical compound, drug        Ammonium persulfate                        Bio-Rad                    Cat\# A3678-100G                                               

  Chemical compound, drug        TEMED                                      Sigma Aldrich              Cat\# T9281-50ml                                               

  Chemical compound, drug        Hydrochloric acid                          Thermo Fisher Scientific   Cat\# A14-500                                                  

  Chemical compound, drug        Agar                                       Sigma Aldrich              Cat\# A1296-1KG                                                

  Chemical compound, drug        IPTG                                       Thermo Fisher Scientific   Cat\# BP1755-10                                                

  Antibody                       Anti-H3K9me2 (Mouse monoclonal)            Abcam                      Cat\# ab1220\                                                  IF (1:1000), WB (1:2500)
                                                                                                       RRID:[AB_449854](https://scicrunch.org/resolver/AB_449854)     

   Antibody                      Anti-H3K9me3\                              Abcam                      Cat\# ab8898\                                                  IF (1:1000), WB (1:5000)
                                 (Rabbit polyclonal)                                                   RRID:[AB_306848](https://scicrunch.org/resolver/AB_306848)     

  Antibody                       Anti-H3 (Rabbit polyclonal)                Abcam                      Cat\# ab1791\                                                  IF (1:1000), WB (1:5000)
                                                                                                       RRID:[AB_302613](https://scicrunch.org/resolver/AB_302613)     

  Antibody                       Anti-H3K4me3\                              Abcam                      Cat\# ab8580\                                                  IF (1:1000), WB (1:1000)
                                 (Rabbit polyclonal)                                                   RRID:[AB_2827504](https://scicrunch.org/resolver/AB_2827504)   

  Antibody                       Monoclonal ANTI-\                          Abcam                      Cat\# F1804-5MG\                                               IF (1:5000), WB (1:5000)
                                 FLAG M2 Antibody                                                      RRID:[AB_262044](https://scicrunch.org/resolver/AB_262044)     

  Antibody                       THE V5 Tag Antibody                        GenScript                  Cat\# A01724-100\                                              IF (1:1000), WB (1:5000)
                                                                                                       RRID:[AB_2827501](https://scicrunch.org/resolver/AB_2827501)   

  Antibody                       Anti-MBP\                                  New England Biolabs        Cat\# E8032S\                                                  WB (1:5000)
                                 (Mouse monoclonal)                                                    RRID:[AB_2827502](https://scicrunch.org/resolver/AB_2827502)   

  Antibody                       Anti-Swi6\                                 Custom                                                                                    WB (1:2500)
                                 (Rabbit polyclonal)                                                                                                                  

  Peptide, recombinant protein   H3K9me3 (1603 Da)                          New England Peptide        Custom                                                         H2N-ARTKQTAR(K9me3)\
                                                                                                                                                                      STGGKA-amide

  Peptide, recombinant protein   H3K9me0 (1560 Da)                          New England Peptide        Custom                                                         ARTKQTKARKSTGGKA-amide

  Peptide,\                      H3K9(me2) (2751 Da)                        Anaspec peptide            Cat\# AS-64359                                                 H-ARTKQTARK(ME2)STGGKAPPKQLAGGK(biotin)-OH
  recombinant protein                                                                                                                                                 

  Peptide,\                      H3K9(me3) (2766 Da)                        Anaspec peptide            Cat\# AS-64360                                                 H-ARTKQTARK(ME3)STGGKAPPKQLAGGK(biotin)-OH
  recombinant protein                                                                                                                                                 

  Peptide, recombinant protein   H3 (2722 Da)                               Anaspec peptide            Cat\# AS-61702                                                 H-ARTKQTARKSTGGKAP\
                                                                                                                                                                      PKQLAGGK(biotin)-OH

  Other                          Dynabeads Protein G                        Thermo Fisher\             LOT\# 00448217                                                 
                                                                            Scientific                                                                                

  Other                          Dynabeads M-280 Streptavidin               Thermo Fisher Scientific   LOT\# 00448388                                                 

  Other                          Dynabeads Protein A                        Thermo Fisher\             LOT\# 00689576                                                 
                                                                            Scientific                                                                                

  Other                          ANTI-FLAG M2\                              Sigma Aldrich              LOT\# A2220-5ML                                                
                                 Affinity Gel                                                                                                                         

  Other                          Amylose Resin                              New England\               LOT\# E8021L                                                   
                                                                            Biolabs                                                                                   

  Other                          Pierce Gutathione Agarose, 100 ml          Thermo Scientific          LOT\# R1241698                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Plasmids {#s4-1}
--------

Plasmids containing Epe1 wild-type and point mutants were constructed by modifying existing pFA6a C-terminal tagging plasmids. Point mutations were introduced by designing primers using guidelines described in Quick Change mutagenesis protocols. A ligation independent cloning approach was used to construct pFastBac vectors containing wild-type Epe1 and Epe1 H297A mutant for recombinant protein expression and also for other MBP fusion constructs for *E. coli* expression. 3X FLAG Swi6^HP1^ and 3X FLAG Chp2^HP1^ were cloned into existing pGEX vectors downstream of the Prescission protease cleavage site using Gibson assembly. The construction of the *10X gal4-10X tetO-ade6^+^* plasmid involved modifying plasmids containing a 10X tetO sequence and sub-cloning Gal4 UAS sequences derived from a *Drosophila* pVALIUM 10X UAS vector. Vectors containing Gal4-Clr3 or Gal4-Sir2 were made using a modified pDual vector with an nmt1 promoter that enables facile integration of DNA sequences at the *leu1* locus in fission yeast ([@bib36]). Further details regarding plasmid construction are readily available upon request.

Strains {#s4-2}
-------

All strains were constructed using a PCR-based gene targeting approach ([@bib6]). In cases where we generated point mutations of *epe1*, we reintroduced the full length wild-type or mutant gene in *epe1Δ* strains. All strains were genotyped using colony PCR assays. We subsequently verified protein expression using western blots for each of the mutant strains. Strains with *10X gal4-10X tetO-ade6^+^* were constructed using a 5-Fluoroorotic Acid (FOA) selection strategy based on disrupting the endogenous *ura4* locus. Strains with Gal4-Clr3 or Gal4-Sir2 were made by digesting pDual vectors with a Not1 restriction enzyme followed by transformations and -LEU based selection. Other deletions of heterochromatin associated factors were achieved either by PCR-based gene targeting approaches or by a cross followed by random spore analysis and PCR based screening to select for colonies that harbored the reporter gene. All strains used in this study are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}, Table S1. Further details regarding strain construction are available upon request.

Cell lysis, co-immunoprecipitation and western blotting {#s4-3}
-------------------------------------------------------

1.5 L of fission yeast cells cells were grown in YEA medium at 32°C to an OD~600~ = 3.5 and harvested by centrifugation. The cell pellets were washed with 10 ml TBS pH 7.5, re-suspended in 1.5 ml lysis buffer (30 mM HEPES pH 7.5, 100 mM NaCl, 0.25% Triton X-100, 5 mM MgCl~2,~1 mM DTT), and the cell suspension was snap-frozen into liquid nitrogen to form yeast 'balls' and cryogenically ground using a SPEX 6875D Freezer/Mill. The frozen cell powder was thawed at room temperature and re-suspended in an additional 10 ml of lysis buffer with protease inhibitor cocktail and 1 mM PMSF. The cell lysates were subjected to two rounds of centrifugation at 18000 rpm for 5 and 30 mins in a JA-25.50 rotor (Beckman). Bradford assay was used to normalize protein levels for co-immunoprecipitation and immunoblot analysis.

Protein G Magnetic Beads were pre-incubated with antibody for 4 h and crosslinked with 10 volumes of crosslinking buffer containing 20 mM DMP (3 mg DMP/ml of 0.2 M Boric Acid pH 9) for 30 min at room temperature by rotating. Crosslinking was quenched by washing twice and incubated with 0.2 M ethanolamine pH 8 for 2 h at room temperature by rotating. The cell lysates were then incubated with antibody crosslinked beads for 3 h at 4°C. Beads were washed three times in 1 ml lysis buffer for 5 mins each, then eluted with 500 μl of 10 mM ammonium hydroxide. The ammonium hydroxide was evaporated using speed vac (SPC-100H) for 5 h and re-suspended in SDS sample buffer. Samples were resolved on SDS--polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membranes. Immunoblotting was performed by blocking PVDF membrane in Tris-buffered saline (TBS) pH 7.5 with 0.1% Tween-20 (TBST) containing 5% non-fat dry milk and subsequently probed with desired primary antibodies and secondary antibodies. Blots were developed by enhanced chemiluminescence (ECL) method and detected with Bio-Rad ChemiDoc Imaging System. All co-IP experiments were reproduced N = 2.

Chromatin immunoprecipitation (ChIP) {#s4-4}
------------------------------------

Cells were grown till late log phase (OD 600--1.3 to 1.8) in yeast extract supplemented with adenine (YEA) or YEA containing tetracycline (2.5 μg/ml) medium and fixed with 1% formaldehyde for 15 min at room temperature (RT). 130 mM glycine was then added to quench the reaction and incubated for 5 min at RT. The cells were harvested by centrifugation, and washed twice with TBS (50 mM Tris, pH 7.6, 500 mM NaCl). Cell pellets were resuspended in 300 μl lysis buffer (50 mM HEPES-KOH, pH 7.5, 100 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, and protease inhibitors) to which 500 μl 0.5 mm glass beads were added and cell lysis was carried out by bead beating using Omni Bead Ruptor at 3000 rpm × 30 s × 10 cycles. Tubes were punctured and the flow-through was collected in a new tube by centrifugation which was subjected to sonication to obtain fragment sizes of roughly 100--500 bp long. After sonication the extract was centrifuged for 15 min at 13000 rpm at 4°C. The soluble chromatin was then transferred to a fresh tube and normalized for protein concentration by the Bradford assay. For each normalized sample, 25 μl lysate was saved as input, to which 225 μl of 1xTE/1% SDS were added (TE: 50 mM Tris pH 8.0, 1 mM EDTA). Dynabeads Protein A were preincubated with Anti-H3K9me2 antibody (PRID:AB_449854). For each immunoprecipitation, 2 μg antibody coupled to 30 μl beads was added to 400 μl soluble chromatin, and the final volume of 500 μl was achieved by adding lysis buffer. Samples were incubated for 2 h at 4°C, the beads were collected on magnetic stands, and washed three times with 1 ml lysis buffer and once with 1 ml TE. For eluting bound chromatin, 100 μL elution buffer I (50 mM Tris pH 8.0, 10 mM EDTA, 1% SDS) was added and the samples were incubated at 65°C for 5 min. The eluate was collected and incubated with 150 μl 1xTE/0.67% SDS in the same way. Input and immunoprecipitated samples were finally incubated overnight at 65°C to reverse crosslink for more than 6 h. 60 μg glycogen, 100 μg proteinase K (Roche), 44 μl of 5M LiCl, and 250 μl of 1xTE was added to each sample and incubation was continued at 55°C for 1 h. Phenol/chloroform extraction was carried out for all the samples followed by ethanol precipitation. Immuno-precipitated DNA was resuspended in 100 μl of 10 mM Tris pH 7.5 and 50 mM NaCl and was used for qPCR (SYBR Green) using an Eppendorf Mastercycler Realplex. For extra crosslinking, prior to fixing with 1% formaldehyde, the cultures were incubated at 18°C for 2 h in a shaking incubator. The cells were pelleted and resuspended in 4.5 ml of 1x PBS. To this 1.5 mM EGS (ethylene glycol bis\[succinimidylsuccinate\]), Pierce (Fisher) was added and the samples were incubated at RT for 20 min with mild shaking before adding 1% formaldehyde. The samples were then processed as mentioned above. All ChIP experiments were reproduced N = 2.

Recombinant protein purification from insect cells and *E. coli* {#s4-5}
----------------------------------------------------------------

MBP-His-TEV-Epe1 and Epe1-ΔC were cloned into a pFastBac vector (Thermo Fisher Scientific) and used for Bacmid generation. Low-titer baculoviruses were produced by transfecting Bacmid into Sf21 cells using Cellfectin II reagent (Gibco). Full-length *S. pombe* Epe1 protein (wild-type and mutant) was expressed in Hi5 cells infected by high titer baculovirus which was amplified from Sf21 cells. After 44 h of infection, Hi5 cells were harvested and lysed in buffer A (30 mM Tris-HCl (pH 8.0), 500 mM NaCl, 5 mM EDTA, 5 mM β-mercaptoethanol with protease inhibitor cocktails) using Emulsiflex-C3 (Avestin). The cleared cell lysate was applied to Amylose resin (New England Biolabs) followed by washing with buffer A and elution with buffer A containing 10 mM maltose. The N-terminal His-MBP tag can be removed by TEV protease cleavage, which was used to evaluate protein solubility. Proteins were further purified using a Superdex 200 (GE Healthcare) size exclusion column. The protein was concentrated in a storage buffer containing 30 mM Tris-HCl (pH 8.0), 500 mM NaCl, 30% glycerol, and 1 mM TCEP.

Proteins were expressed in BL21 (DE3) cells. Cells were grown to log phase at 37°C, cooled on ice, and induced with 0.3 mM IPTG before incubation for 18 h at 18°C. Pellets were suspended in tris buffered saline (TBS) and frozen at −80°C until further use. For purification, cell pellets were thawed in lysis buffer (500 mM NaCl, 50 mM Tris pH 7.5, 10% glycerol) supplemented with protease inhibitor and cells were ruptured using sonicator. Cell debris was removed by centrifugation and the supernatant was incubated with appropriate beads for each purification for 3 h at 4°C. We used a GST tag and glutathione beads (GST) beads for 3X FLAG Swi6^HP1^, Swi6^HP1^ W104A, Swi6^HP1^ loop-X mutant and 3X FLAG-Chp2^HP1^ purifications. Swi6^HP1^ and Chp2^HP1^ were subject to overnight cleavage with Prescission protease. We used an MBP tag and amylose resin for the purification of Epe1^434-948^ and Epe1^434-600^. After washing, Epe1^434-948^ and Epe1^434-600^ were eluted with elution buffer (lysis buffer + 20 mM maltose + 5 mM EDTA). To purify Swi6^HP1^ used for in vitro binding assays, we used a hexahistidine tag and Nickel resin. After elution, the N-terminal 6X His tag was removed using a SUMO protease followed by addition purification using an anion exchange column.

In vitro binding assay {#s4-6}
----------------------

In vitro binding assays were performed by immobilizing recombinant 3X FLAG- Swi6^HP1^ or 3X FLAG- Chp2^HP1^ on 25 μl of FLAG M2 beads, which were incubated with three different concentrations of recombinant MBP fusion proteins in 600 μl binding buffer containing 20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM MgCl~2, ~10% glycerol, 0.25% Triton -X 100, 1 mM DTT. Reactions were incubated at 4°C for 2 h and washed three times in 1 ml washing buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM MgCl~2, ~10% glycerol, 0.25% Triton -X 100, 1 mM DTT) for 5 min each, then 30μl of SDS sample buffer was added followed by incubation at 95°C for 5 min. Proteins were separated through SDS-PAGE and transferred to PVDF membrane followed by incubation with anti-MBP monoclonal antibody (E8032S, NEB) and M2 Flag antibody (A8592, Sigma). Depending on the experiment, we added co-factors 100μM ammonium iron (II) sulfate hexahydrate and 1 mM α-ketoglutarate or 5μg of H3 peptides (1--21 amino acids) with or without modifications. Western blot data for in vitro binding assays were analyzed using ImageJ software. The exposure times for the interaction assays were chosen and differ in each experiment to capture differences in the interaction between Epe1 and Swi6 depending on the assay conditions. Assays performed on different blots cannot be compared but samples loaded on the same blot can be readily compared to each other. All in vitro binding experiments were reproduced N ≥ 3.

Demethylase assay {#s4-7}
-----------------

Mass spectrometry-based demethylase assays were performed using 5μg MBP-Epe1, 10μg Swi6, and 20μM peptide (either H3K9me3 or H3K9me2). The peptide sequences used in these assays were as follows: 1) NH~2~-ARTKQTAR(K9me3)STGGKA-amide (H3K9me3, 1--15 amino acids). 2) H- ARTKQTARK(K9me2)STGGKAPRKQLA - OH) (H3K9me2, 1--21 amino acids). The demethylase assay reaction buffer consists of 50 mM HEPES (pH 7.5), 50 mM NaCl, 100 μM ammonium iron (II) sulfate hexahydrate, 1 mM L-ascorbic acid, and 1 mM α-ketoglutarate. Reaction mixtures were incubated at 37°C for 3 h, quenched with an equal volume of 1% trifluoroacetic acid, and stored at −20°C. In parallel, we also performed demethylase assays using equivalent amounts of purified JMJD2A (protein amounts equalized using SDS-PAGE gels). Samples were thawed and desalted using a ZipTip (Millipore). The ZipTip was first equilibrated twice with wetting solution (50% acetonitrile) and twice with equilibration solution (0.1% trifluoroacetic acid). Samples (10μl) following the demethylase assay were washed with washing solution (0.1% trifluoroacetic acid) before elution with 4μl of 0.1% trifluoroacetic acid/50% acetonitrile. Matrix-assisted laser desorption ionization (MALDI) mass spectrometry was performed using a Waters Tofspec-2E in reflectron mode with delayed extraction (Department of Chemistry, University of Michigan). All demethylase experiments were reproduced N = 2.

In vitro translation (IVT) assays {#s4-8}
---------------------------------

To identify minimal Epe1 fragments that bind to Swi6^HP1^, Epe1 fragments were translated in vitro using TNT T7-coupled reticulocyte lysate (Promega) with ^35^S-labeled methionine (Roche). In vitro translated target proteins were incubated with Flag-tagged Swi6 at 4°C for 20 min. M2 FLAG beads pre-equilibrated with buffer B containing 30 mM Tris-HCl (pH 8.0), 50 mM NaCl, 1 mM DTT, and 0.1% NP-40 (w/v) were mixed and incubated at 4°C for 45 min with rotation. The beads were washed three times with buffer B, and bead-bound proteins were separated by SDS-PAGE. Dried gels were analyzed by overnight exposure of a phosphor imager plate.

In vitro binding assays using fission yeast cell extracts {#s4-9}
---------------------------------------------------------

To generate fission yeast cell lysates, we grew 100 ml of fission yeast cells in YEA medium at 32°C to an OD~600~ = 3--3.5 and harvested cells by centrifugation. The cell pellets were washed with 1 ml TBS pH 7.5 and resuspended in lysis buffer (30 mM HEPES pH 7.5, 100 mM NaCl, 0.25% Triton X-100, 5 mM MgCl2, 1 mM DTT). 0.5 mm glass beads were added and cell lysis was carried out by bead beating using Omni Bead Ruptor at 3000 rpm (30 s x eight cycles). The cell extract was centrifuged for 20 min at 15000 rpm at 4°C and the lysates were incubated with beads pre-bound with recombinant MBP-Epe1^434-948^ protein for 3 h at 4°C. Beads were washed three times with 1 ml lysis buffer and proteins were eluted by boiling the beads in SDS sample buffer. Proteins were resolved by SDS-PAGE and analyzed by immunoblotting with appropriate primary and secondary antibodies.

To test whether the N- and C-terminal fragments of Epe1 binds in *trans*, we used the following protocol: 1.5 l of fission yeast cells expressing 3XFLAG- Epe1-N (1-434) were grown in YEA medium at 32°C to an OD~600~ = 3.5 and harvested by centrifugation. The cell pellets were washed with 10 ml TBS pH 7.5, re-suspended in 1.5 ml lysis buffer (30 mM HEPES pH 7.5, 100 mM NaCl, 0.25% Triton X-100, 5 mM MgCl~2,~1 mM DTT), and the cell suspension was snap-frozen into liquid nitrogen to form yeast 'balls' and cryogenically ground using a SPEX 6875D Freezer/Mill. The frozen cell powder was thawed at room temperature and re-suspended in an additional 10 ml of lysis buffer (30 mM HEPES pH 7.5, 100 mM NaCl, 0.25% Triton X-100, 5 mM MgCl~2~, 1 mM DTT) with protease inhibitor cocktail and 1 mM PMSF. The cell lysates were subjected to two rounds of centrifugation at 18000 rpm in a JA-25.50 rotor (Beckman). Protein G Magnetic Beads were pre-incubated with an M2 FLAG antibody and the antibodies were crosslinked to the beads prior to usage. The cell lysates expressing 3X FLAG-Epe1-N (1-434) were then incubated with the M2 FLAG antibody conjugated beads overnight at 4°C. Beads were washed once in 1 ml lysis buffer. Importantly, 3XFLAG-Epe1-N (1-434) was retained on beads for subsequent binding assays. Recombinant Swi6^HP1^ (1 μg) was pre-incubated with recombinant MBP-Epe1^434-948^ for 1 h in lysis buffer, then this was added to beads pre-bound with the 3XFLAG-Epe1-N (1-434) fragment.

In assays where we tested the effect of modified peptides on the *trans* interaction between the N- and C-terminal halves of Epe1, we added 1 μg of either H3K9me0 or K9-trimethyl H3 (H3K9me3) peptides. Immunoblotting was performed by blocking PVDF membrane in TBS pH 7.5 with 0.1% Tween-20 (TBST) containing 5% non-fat dry milk and subsequently probed with desired primary antibodies and secondary antibodies. Blots were developed with the ECL method and detected with Bio-Rad ChemiDoc Imaging System.

Streptavidin pull-down assay {#s4-10}
----------------------------

H3K9me0 or H3K9me3 biotinylated peptides (50 nM) were pre-incubated with either recombinant MBP-Epe1 or 3XFLAG-Swi6 in binding buffer (30 mM Tris-HCI \[pH 7.5\], 600 mM NaCl, 1% Triton X-100, 5% glycerol, 2.5% BSA) for 1 h at 4°C. Then streptavidin M280 beads (Invitrogen) were added to the pre-mixed protein-peptide mixture and incubated for an additional 2 h at 4°C. The beads were then rinsed three times with wash buffer (30 mM Tris-HCI \[pH 7.5\], 600 mM NaCl, 1% Triton X-100, 5% glycerol, 2.5% BSA) and bound proteins were eluted by boiling the beads in SDS sample buffer. The input and bound proteins were resolved by SDS-PAGE and analyzed by immunoblotting with MBP antibody (E8032S, NEB).

MBP pull-down assays were performed using Calf thymus histones (Sigma) to evaluate Epe1 binding specificity. 1 μg of Calf thymus histones (Sigma) were pre-incubated with recombinant MBP-Epe1 in binding buffer (30 mM Tris-HCI \[pH 7.5\], 600 mM NaCl, 1% Triton X-100, 5% glycerol, 2.5% BSA) for 1 h at 4°C. Amylose resin was added to the binding assay and incubated for an additional 2 h at 4°C. Beads were rinsed three times with wash buffer (30 mM Tris-HCI \[pH 7.5\], 600 mM NaCl, 1% Triton X-100, 5% glycerol, 2.5% BSA) and bound proteins were eluted by boiling the beads in SDS sample buffer. The input and bound proteins were resolved by SDS-PAGE and analyzed by immunoblotting with MBP antibody (E8032S, NEB).
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This paper identifies a non-enzymatic function in counteracting heterochromatin for the putative histone demethylase Epe1. The presented data suggest that binding of Epe1 to histone H3 methylated at lysine 9 -- a hallmark of heterochromatin -- enables Epe1 to interact with the key heterochromatin protein Swi6 by releasing an autoinhibitory conformation. The results highlight the possibility that putative enzymes may have non-catalytic modes of action that are as important or more important than catalytic ones.

**Decision letter after peer review:**

\[Editors' note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.\]

Thank you for submitting your work entitled \"An auto-inhibitory mechanism regulates the non-enzymatic functions of a histone demethylase\" for consideration by *eLife*. Your article has been reviewed by four peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Yota Murakami (Reviewer \#3).

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work in its present form will not be considered further for publication in *eLife*.

The reviewers agreed that the mechanism by which Epe1 counteracts heterochromatic silencing is of great interest. The reviewers were also intrigued by the proposal that Epe1 autoinhibition is relieved by interaction with H3K9me, which enables Epe1 to bind Swi6, thereby displacing heterochromatin-promoting factors such as Clr3. However, there was strong consensus that key aspects of the model -- Epe1 autoinhibition, and the release of autoinhibition by direct interaction with H3K9me -- are not strongly supported by the data. The proposed Epe1 noncatalytic mechanism was also not strongly supported and the overall model of Epe1 action has important unstated implication that should be considered and discussed. We would be willing to consider a resubmitted manuscript that convincingly demonstrates how H3K9me affects Epe1 conformation and function and presents a clear, well-supported model of Epe1 anti-silencing activity.

Reviewer \#1:

This manuscript investigates how Epe1, a putative histone demethylase for which catalytic activity has not been demonstrated, counteracts epigenetic silencing in *S. pombe*. The authors show that mutations in residues predicted to be involved in cofactor binding disrupt Epe1 activity, prevent its localization to heterochromatin, and disrupt its interaction with Swi6. Loss of Swi6 or H3K9me prevents Epe1 from localizing to heterochromatin. The authors show that Epe1 interacts with Swi6 via a region adjacent to the JmjC domain, that this domain interacts more strongly with Swi6 in isolation than in the context of the entire Epe1 protein, and that expression of this domain (lacking JmjC) can counteract heterochromatic silencing. The authors also show that the N- and C-terminal halves of Epe1 interact in vitro. Interaction between Epe1 and Swi6 is stimulated by H3K9me in vitro, and a mutation that reduces Swi6 affinity for H3K9me does not eliminate this effect. Finally, the authors show that tethering the histone deacetylase Clr3 to heterochromatin can overcome the anti-silencing function of Epe1. The authors propose that Epe1 exists in an auto-inhibited conformation which is relieved by interaction with H3K9me, allowing Epe1 to interact with Swi6, which in turn counteracts silencing via a non-enzymatic mechanism that involves displacing silencing proteins, such as Clr3, that are recruited by Swi6.

This manuscript contains a great deal of interesting results, but I feel that two of the key conclusions are supported by weak or ambiguous data.

First, the authors propose that Epe1 has a noncatalytic mode of anti-silencing. This is based on (1) the ability of a Swi6-interactin domain (lacking JmjC) of Epe1 to counteract heterochromatic silencing, (2) the ability of cofactor binding mutations to disrupt Epe1 localization, and (3) the demonstration that tethering the histone deacetylase Clr3 to heterochromatin can overcome the anti-silencing function of Epe1. However, the first result is quite artificial and does not show that the whole Epe1 protein, expressed at endogenous levels, has a noncatalytic anti-silencing mode. The authors don\'t know how their mutations interfere with Swi6 binding, and therefore the second result doesn\'t to me argue for a noncatalytic activity. Same of Clr3 tethering -- I find it equally plausible that Clr3 and Epe1 have antagonistic catalytic activities, and tethering Clr3 tips the balance in favour of heterochromatin. I don\'t find the claim for a noncatalytic function of Epe1 to be strongly supported.

Second, the authors propose that binding of H3K9me to Epe1 relieves Epe1 autoinhibition and enables Epe1 to interact with Swi6. This is supported by the observations that (1) a domain of Epe1 interacts more strongly than the entire protein with Swi6 in vitro, that (2) the N- and C-terminal halves of Epe1 interact in vitro, that (3) the interaction between Epe1 and Swi6 is stimulated by H3K9me in vitro, that (4) a mutation that reduces Swi6 affinity for H3K9me does not eliminate this effect, and that (5) several mutations disrupt Epe1 localization to heterochromatin and binding to Swi6. However, the first two lines of evidence do not demonstrate autoinhibition, they just show in vitro effects that are consistent with autoinhibition and may not be relevant in vivo. The evidence that H3K9me stimulates the interaction with Swi6 via binding to Epe1 is weak and indirect. The authors do not demonstrate H3K9me binding to Epe1 and do not identify the domain responsible for this. The authors also do not know how the cofactor binding mutations disrupt Epe1 interaction with Swi6. The conclusion that binding of H3K9me to Epe1 relieves Epe1 autoinhibition and enables Epe1 to interact with Swi6 remains a hypothesis.

I am particularly concerned by the weak evidence because I find the overall model proposed by the authors counterintuitive (or at least nonintuitive). A simple model would be that the interaction between H3K9me and Swi6 increases the local concentration of Swi6 at heterochromatin (facilitated by the protein\'s phase transition properties), which allows Epe1 to bind. But the authors add a major complication -- interaction between H3K9me and Epe1 is also required. In this model, Epe1 must interact with H3K9me and Swi6, but it is also competing with Swi6 for H3K9me binding. Is this competition important? Can tethering of Swi6 to chromatin recruit Epe1 in the absence of H3K9me? I feel that the authors\' model needs substantially more support than is currently provided.

Reviewer \#2:

In fission yeast, Epe1 is a putative histone demethylase that plays important roles in regulating the heterochromatin landscape. However, the mechanism by which Epe1 functions is not clear.

In this manuscript, the authors found that point mutations that abolish co-factor binding in the JmjC domain can disrupt Epe1\'s binding with Swi6 and also reduces Epe1 localization at heterochromatin. in vitro binding assays confirmed that one Epe1 mutant (H297A) has significantly reduced binding with Swi6. Truncation analysis mapped the Swi6 interaction interface to Epe1 433-630, which is outside of the JmjC domain. Moreover, Epe1 433-630 interacts with Swi6 stronger than full length Epe1, which led the authors to hypothesize that full-length Epe1 might adopt an auto-inhibitive conformation to prevent its binding with Swi6. Indeed, the authors found that Epe1\'s N-terminal region can bind to its C-terminal region. Authors further demonstrated that H3K9me3 is required for Swi6-Epe1 interaction in vivo and that H3K9me3 peptide enhanced Swi6-Epe1 interaction in vitro, but not Epe1-H29&A. These results suggest a mechanism for Epe1 to only interact with Swi6 at heterochromatin regions. Lastly, the authors showed that Epe1 blocks Swi6\'s interaction with Clr3, an HDAC important for heterochromatin assembly.

Overall, the data quality is high and the proposed model is very interesting. The findings will be of high interest to the heterochromatin field. I would recommend its publication after addressing several major questions.

1\) The model suggests that the JmjC domain of Epe1 binds to H3K9me3 and that the H297A mutation affects this binding. Since the authors have recombinant proteins at hand, they should test these interactions.

2\) The model also suggests that in the presence of H3K9me3, interaction between Epe1\'s N- and C-terminal regions will be reduced. This should also be tested.

3\) In Figure 4, there appears to be very weak binding of WT Epe1 with Swi6 without H3K9me3 peptide. This is very different from results shown in Figures 2 and 3. What\'s the reason for this discrepancy?

4\) Clr3∆ or Sir2∆ has different effects on H3K9me at centromeres, mating type region, and telomeres. If the hypothesis is correct, it is expected that Epe1 localization will change differently at different locations. ChIP analysis of Epe1 will complement Figure 4B and strengthen the hypothesis.

*Reviewer \#3:*

The putative histone demethylase Epe1 in fission yeast has been shown to localize heterochromatin via interaction with a HP1 homologue Swi6 and antagonize heterochromatin formation probably through its JmjC-domain dependent demethylation activity, though the enzymatic activity has not been detected in vitro. In this manuscript, authors made several interesting observations. (1) JmjC-domain mutants of Epe1 loose interaction with Swi6 and heterochromatin localization. (2) Epe1 interacts with Swi6 via its C-terminal half that does not include JmjC domain. (3) Epe1 N-terminal half including JmjC-domain interacts with C-terminal half in *trans*. (5) H3K9me peptide enhance interaction between Swi6 and Epe1. (4) Expression of C-terminal half Epe1 antagonize maintenance of heterochromatic silencing with non-enzymatic activity. (6) Mutation of JmjC domain strengthen the interaction between Swi6 and Clr3, a Swi6-binding silencing factor. (7) Artificial recruitment of Clr3 supports maintenance of heterochromatin in the presence of wild type Epe1. Taken together authors claimed that Epe1-Swi6 binding is auto-inhibited by cis-interaction between N-terminal half and C-terminal half of Epe1. The auto-inhibition can be released by H3K9 methylation and Epe1 compete with Clr3 for Swi6-binding resulting in removal of heterochromatin.

Author\'s model is novel and interesting in terms of regulatory mechanism of heterochromatin by Epe1. However, their model is not fully supported by their experimental data. There is no direct evidence showing Epe1 N-terminal half and C-terminal half interacts in cis. Their result can be also explained by *trans*-interaction. Moreover, they did not present direct evidence showing this interaction is inhibitory to Swi6 binding. This could be tested by adding N-terminal half in the in vitro binding assay of Epe1^434-948^ and Swi6 (Figure 3A). In addition, If H3K9me peptide release the auto inhibition through Epe1 as author claimed, addition of H3K9me peptide in the in vitro binding assay would disrupt interaction between N- and C-terminal half of Epe1. Furthermore, I think one of the main point of their model is that competition between Epe1 and Clr3 for Swi6, by which Epe1 inhibits stable maintenance of artificially formed heterochromatin. However, the evidence for this mechanism is not enough. At least, they should check localization of Clr3 at artificial heterochromatin by ChIP analysis. If their model is correct, amount of Clr3 at artificial heterochromatin (-Tet) would increase in *epe1*∆ or *epe1*-H297A cells and decreased in the presence of Epe1 or Epe1^434-948^.

Recent paper (Sorida et al., 2019), showed that N-terminal domain that does not include jmjC domain has transcription activation activity and deletion of this domain caused severe loss of Swi6 binding and heterochromatin localization of Epe1. In addition, they showed H297A mutation also caused reduction of Swi6 binding. Probably, this paper published after the submission of this manuscript, but authors should mention and discuss about this paper in the revised manuscript.

In conclusion, this manuscript presents novel data and their model will attract interests of many readers, but the points I described above should be clarified before publication.

\[Editors' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for submitting your article \"An auto-inhibitory mechanism regulates the non-enzymatic functions of a histone demethylase\" for consideration by *eLife*. Your article has been reviewed by four peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Kevin Struhl as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Songtao Jia (Reviewer \#2); Yota Murakami (Reviewer \#4).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Since the discovery of the JmjC domain as the catalytic region of histone demethylases, the molecular function of Epe1 in fission yeast has been under intense debate, and no demethylase activity has been shown. Interest in this protein intensified with the finding that H3K9me can be inherited without initiation signals, but only in an *epe1* mutant background. The assumption has been that Epe1 is a H3K9 demethylase, with the supporting evidence that *epe1* mutants expected to abolish demethylase activity also abolished Epe1 function. This manuscript provides detailed characterization of these mutations, challenging the hypothesis that they abolish demethylase activity. Instead, this paper identifies a non-enzymatic function for Epe1 -- binding to Swi6 -- that is regulated by H3K9me. The authors\' data also suggest, but do not prove yet, that binding of Epe1 to H3K9me enables Epe1 to interact with Swi6 by releasing an autoinhibitory conformation. The results highlight the possibility that proteins that appear to be primarily enzymes may have non-catalytic modes of action that are as important or more important than catalytic ones.

Essential revisions:

1\) The most important outstanding concern is about the interaction between H3K9me3 and Epe1. This interaction is central to the authors\' hypothesis yet is tested only with the entire Epe1 protein and reported in two supplementary panels. One concern is that the model presented by the authors -- that Swi6 and Epe1 may not compete for H3K9me tails -- depends on the binding affinities of these proteins for H3K9me. There are significantly fewer H3K9me tails (\~2000 nucleosomes) in fission yeast than Swi6 molecules (\~20,000, Sadaie, 2008), which would argue that only molecules at the affinity of Swi6 for H3K9me2/3, or tighter, could access tails. Co-occupancy of Swi6 and Epe1 of adjacent tails therefore is possible only in a circumstance where the affinity of Epe1 is at least as high as that of Swi6 (which is not terribly high, measured at \~2-15 µM depending on the group), given the substantial Swi6 excess. The easiest way to show that H3K9me binding by Epe1 directs its assembly on chromatin is to mutate the region or residues required for this recognition and test its impact.

Given the many available truncation constructs, the authors should be able to identify the domain that interacts with H3K9me and determine the affinity of the interaction. As previously suggested, the JmjC domain is a good candidate for H3K9me binding. These data could be used to generate a mutant that abolishes binding, and the mutant phenotypes should be tested in vivo. These experiments would be very important to support the authors\' conclusions.

2\) The presented data clearly indicate that an H3K9me peptide can disrupt the interaction between the N-terminal and C-terminal domains of Epe1. However, the authors have not tested if the addition of the N-terminal half inhibits the interaction between the C-terminus and Swi6. This would provide support for the authors\' autoinhibition model.

3\) The presented experiments strongly suggest, but do not prove, an autoinhibitory mechanism, as there are no experiments that directly address Epe1 conformation. Therefore, claims regarding such a mechanism should be softened. The title could be changed to \"Interaction with histone H3 methylated at lysine 9 regulates the non-enzymatic functions of the putative histone demethylase Epe1\" or something similar, and strong claims like \"An auto-inhibitory conformation regulates the non-enzymatic properties of Epe1 through its interaction with Swi6\" in the Abstract should be amended or removed.

10.7554/eLife.53155.sa2

Author response

\[Editors' note: the authors resubmitted a revised version of the paper for consideration. What follows is the authors' response to the first round of review.\]

> The reviewers agreed that the mechanism by which Epe1 counteracts heterochromatic silencing is of great interest. The reviewers were also intrigued by the proposal that Epe1 autoinhibition is relieved by interaction with H3K9me, which enables Epe1 to bind Swi6, thereby displacing heterochromatin-promoting factors such as Clr3.
>
> However, there was strong consensus that key aspects of the model -- Epe1 autoinhibition, and the release of autoinhibition by direct interaction with H3K9me -- are not strongly supported by the data. The proposed Epe1 noncatalytic mechanism was also not strongly supported and the overall model of Epe1 action has important unstated implication that should be considered and discussed. We would be willing to consider a resubmitted manuscript that convincingly demonstrates how H3K9me affects Epe1 conformation and function and presents a clear, well-supported model of Epe1 anti-silencing activity.

Since our initial submission, we have added experimental data that addresses some of the key issues highlighted by reviewers and editors, including, support for a model based on auto-inhibition, H3K9 methylation dependent release from auto-inhibition and additional evidence for a non-catalytic function associated with Epe1. We have also edited our Discussion section in light of recent work from the Murakami lab outlining a non-enzymatic function for the Epe1 N-terminus (Sorida et al., 2019). We have considered the implications of our work and how this affects current models of epigenetic inheritance in a revised Discussion section. The result of our efforts is twelve new figure panels, substantial edits to the manuscript and a critical assessment of reviewer feedback.

This significant update to the manuscript was made possible by four key experiments (along with several minor/additional revisions) that we have summarized here:

1\) We detected a direct binding interaction between Epe1 and an H3K9me3 peptide and H3K9 methylated histones. Epe1 also exhibits specificity towards H3K9 methylated as opposed to H3K4 methylated histones (Figure 2---figure supplement 1H-I).

2\) We also directly demonstrate that the interaction between the Epe1 N- and C-terminus in *trans* can be disrupted upon addition of an H3K9me3 peptide. These results lend strong support to a model where Epe1 is preserved in an auto-inhibited state with H3K9 methylation reversing this inhibition (new Figure 5A).

3\) We identified and purified a C-terminal truncation mutant of Epe1, (Epe1-ΔC) which exhibits a substantial increase in its interaction with Swi6 relative to the full-length protein even in the absence of a modified peptide. Furthermore, Epe1-ΔC does not undergo an H3K9me3 dependent enhancement in its interaction with Swi6 unlike its full-length counterpart.

Collectively, these results clearly support our notion that the C-terminus of Epe1 plays a critical role in enforcing an H3K9 methylation dependent mode of interaction with Swi6 (new Figure 5B-E).

We designed a completely novel ectopic silencing approach in fission yeast to provide additional evidence for a non-catalytic function associated with the Epe1 C-terminus. Since Epe1 interacts with Swi6 and excludes other effector molecules, we hypothesized that Swi6 mediated heterochromatin initiation would be highly sensitive to Epe1 activity (enzymatic or nonenzymatic). We expressed the C-terminus of Epe1 (434-948) which lacks the JmjC domain in cells where a TetR-Swi6 CSD fusion has been tethered. The C-terminal fragment expression now completely blocks heterochromatin formation at the ectopic site. These results clearly support a model where the non-enzymatic function of Epe1 relies on its Swi6 interaction (Figure 3E and Figure 3C).

> Reviewer \#1:
>
> \[...\] This manuscript contains a great deal of interesting results, but I feel that two of the key conclusions are supported by weak or ambiguous data.

We thank the reviewer for his/her positive comments about our findings. We have sought to address concerns raised about the ambiguity of our data and our interpretations through additional experiments. Our new experiments lend strong support to our proposed model and we hope that our new findings will alleviate these concerns.

> First, the authors propose that Epe1 has a noncatalytic mode of anti-silencing.

The premise of our studies is based on prior work revealing a non-enzymatic basis for Epe1 in resetting epigenetic silencing (Trewick et al., 2005; Zofall et al., 2006). The overexpression of Epe1 point mutants that lack any catalytic functions completely restores normal levels of reporter gene silencing in *epe1*Δ cells. Recent studies have further substantiated these early findings and suggest that Epe1 might have a critical role in activating transcription within pericentromeric repeats (Bao et al., 2019; Sorida et al., 2019). Our studies, viewed in this broader context, adds a strong mechanistic perspective to this urgent question through stringent biochemical analysis.

> This is based on (1) the ability of a Swi6-interactin domain (lacking JmjC) of Epe1 to counteract heterochromatic silencing, (2) the ability of cofactor binding mutations to disrupt Epe1 localization, and (3) the demonstration that tethering the histone deacetylase Clr3 to heterochromatin can overcome the anti-silencing function of Epe1. However, the first result is quite artificial and does not show that the whole Epe1 protein, expressed at endogenous levels, has a noncatalytic anti-silencing mode. The authors don\'t know how their mutations interfere with Swi6 binding, and therefore the second result doesn\'t to me argue for a noncatalytic activity.

We thank the reviewer for this important critique. Although we do not know the mechanism that leads to the loss of interaction between Epe1 JmjC mutants and Swi6, we can unambiguously catalog the molecular consequence of the loss of their interaction. We demonstrate that a loss of interaction between the full-length Epe1 JmjC mutant (expressed at endogenous levels) and Swi6 is compensated by a gain of an interaction between a heterochromatin enhancer, Clr3 and Swi6 (Figure 6A). Therefore, we disagree that our manuscript does not establish a non-enzymatic function associated with Epe1 when the full-length protein has been expressed at endogenous levels.

Our tethering experiments were designed based on findings in Figure 6A to overcome the need for Swi6 to be involved in Clr3 recruitment to sites of heterochromatin formation. We were surprised that the tethering experiments conformed to our expectations where Clr3 recruitment appears to be rate-limiting for epigenetic inheritance. Intriguingly, our ectopic system recapitulates a DNA sequence dependent maintenance mechanism where Atf1/Pcr1 (two DNA binding proteins) are thought to recruit Clr3 to the fission yeast mating type locus (Wang et al., 2017). Therefore, the Clr3 tethering approach recapitulates what potentially occurs in fission yeast cells at natural loci.

Our Discussion section is agnostic about the possibility of Epe1 having an additional enzymatic function. We certainly have not ruled out this possibility. We have stated that the expression of the Epe1 C-terminus only partially suppresses heterochromatin assembly. It is eminently possible that our reconstitution conditions failed to capture histone demethylation. Our Discussion section highlights some potential strategies to consider while attempting to reconstitute its putative catalytic functions. We have added the following lines to the Discussion:

"Nevertheless, given the similarity of the JmjC domain of Epe1 to active demethylases, we favor a model where different proteins that interact with Epe1 could act as positive or negative allosteric regulators. For example, Bdf2, a BRD4 homolog that localizes to heterochromatin boundaries along with Epe1, represents a possible candidate that activates its latent enzymatic functions given that H3K9 methylation levels are negligible at the heterochromatin-euchromatin interface (Wang et al., 2013)."

> Same of Clr3 tethering -- I find it equally plausible that Clr3 and Epe1 have antagonistic catalytic activities, and tethering Clr3 tips the balance in favour of heterochromatin. I don\'t find the claim for a noncatalytic function of Epe1 to be strongly supported.

It is important to note that whether Clr3 acts directly or indirectly to oppose Epe1 activity does not negate the central claims of our manuscript. Nevertheless, we deeply appreciate and recognize the need to be cautious with regards to our conclusions. Hence, we have amended the Results section of the manuscript relating to the Clr3 tethering experiments to explicitly state:

"We hypothesized that directly tethering Clr3 at an ectopic site would eliminate its dependency on Swi6 to localize at sites of heterochromatin formation. In this genetic context, we rationalized that Epe1 would be unlikely to counteract Clr3 recruitment. One caveat of this experimental strategy is that it does not rule out the possibility that Epe1 and Clr3 have antagonistic catalytic activities but simply seeks to test whether Clr3 recruitment itself might be rate-limiting at sites of heterochromatin formation."

> Second, the authors propose that binding of H3K9me to Epe1 relieves Epe1 autoinhibition and enables Epe1 to interact with Swi6. This is supported by the observations that (1) a domain of Epe1 interacts more strongly than the entire protein with Swi6 in vitro, that (2) the N- and C-terminal halves of Epe1 interact in vitro, that (3) the interaction between Epe1 and Swi6 is stimulated by H3K9me in vitro, that (4) a mutation that reduces Swi6 affinity for H3K9me does not eliminate this effect, and that (5) several mutations disrupt Epe1 localization to heterochromatin and binding to Swi6. However, the first two lines of evidence do not demonstrate autoinhibition, they just show in vitro effects that are consistent with autoinhibition and may not be relevant in vivo. The evidence that H3K9me stimulates the interaction with Swi6 via binding to Epe1 is weak and indirect. The authors do not demonstrate H3K9me binding to Epe1 and do not identify the domain responsible for this. The authors also do not know how the cofactor binding mutations disrupt Epe1 interaction with Swi6. The conclusion that binding of H3K9me to Epe1 relieves Epe1 autoinhibition and enables Epe1 to interact with Swi6 remains a hypothesis.

We have now included three independent lines of experimental evidence to support our claims:

1\) We tested the direct interaction between Epe1 and an H3K9me3 peptide and H3K9 methylated histones. Our binding assays clearly detect a direct interaction between Epe1 and an H3K9me3 peptide as opposed to an unmodified H3K9me0 peptide. Furthermore, Epe1 selectively interacts with H3K9 methylated histones as opposed to H3K4 methylated histones. These data have now been added to the revised version of the manuscript (Figure 2---figure supplement 1H and I).

2\) To identify a potential domain within Epe1 that enforces an H3K9 methylation dependent mode of interaction with Swi6, we generated a C-terminal truncation mutant (Epe1-ΔC). Using in vitroand in vivomeasurements: We demonstrate that Epe1-ΔC exhibits a significantly higher degree of binding to Swi6 (Figure 5B-C). Furthermore, Epe1-ΔC fails to exhibit any H3K9me3 peptide dependent stimulation (Figure 5D). Epe1-ΔC binds to Swi6 in cells in the presence or absence of the H3K9 methyltransferase, *clr4*D (Figure 5E). We conclude that the C-terminus of Epe1 enforces an H3K9 methylation dependent mode of interaction between Epe1 and Swi6.

These data have now been added as a new figure to the revised version of our manuscript (new Figure 5B-E).

3\) To test whether H3K9 methylation reverses an auto-inhibitory conformation of Epe1, we measured the interaction between the N- and C-terminal Epe1 fragments in the presence or absence of an H3K9me3 peptide. The addition of an H3K9me3 peptide disrupts the direct interaction between the N- and C-terminal Epe1 fragments in *trans.* This data has now been added to the revised version of the manuscript (new Figure 5A).

> I am particularly concerned by the weak evidence because I find the overall model proposed by the authors counterintuitive (or at least nonintuitive). A simple model would be that the interaction between H3K9me and Swi6 increases the local concentration of Swi6 at heterochromatin (facilitated by the protein\'s phase transition properties), which allows Epe1 to bind. But the authors add a major complication -- interaction between H3K9me and Epe1 is also required.

We initially considered and spent considerable time and effort exploring a model where Swi6 phase separation facilitates Epe1 binding. However, new and existing biochemical lines of evidence that we have presented in this manuscript forced us to re-evaluate these early assumptions. In particular, the most striking findings that contradict this model are:

1\) A Swi6 chromodomain mutant (Swi6 W104A) that fails to bind to H3K9 methylated histones nevertheless undergoes a substantial increase in its interaction with Epe1 in the presence of an H3K9me3 peptide (Figure 4---figure supplement 1D).

2\) An Epe1 C-terminal truncation mutant, Epe1-ΔC, does not undergo any stimulation in its interaction with wild-type Swi6 in the presence of an H3K9me3 peptide (Figure 5D).

3\) A *trans* interaction between the Epe1 N- and C- terminus can be disrupted by an H3K9me3 peptide bolstering our case for a model predicated on Epe1 being responsive to the presence of H3K9 methylation (Figure 5A).

Based on these observations, we envision a model where H3K9 methylation promotes the cooperative assembly of a heterochromatin inhibitory complex comprised of Epe1 and Swi6. The model where the phase separation properties of Swi6 drive Epe1 recruitment is not fully supported by our data.

> In this model, Epe1 must interact with H3K9me and Swi6, but it is also competing with Swi6 for H3K9me binding. Is this competition important?

The question of competing interactions between Epe1 and Swi6 for H3K9 methylated histone tails is undoubtedly an interesting and contentious point to consider. This is never an issue in our experiments where our in vitroassays are supplemented with an excess of histone H3K9me3 peptide. In cells, it is equally plausible that the multivalency of heterochromatin leads to non-competitive complex assembly wherein Epe1 and Swi6 bind to adjacent or distal nucleosomes. Given the dense networks of H3K9 methylation at sites of constitutive heterochromatin, we favor a model where the two proteins need not have to compete for the same binding site. We have added a line in our Discussion section which highlights how Swi6 and Epe1 could potentially compete for a shared binding site:

"The ability of Epe1 to bind to H3K9 methylation raises the possibility that it competes with Swi6 for a shared binding site. However, heterochromatin consists of dense networks of H3K9 methylation. It is possible that Epe1 while interacting with Swi6 could undergo stimulation via an interaction with an adjacent or a distal nucleosome eliminating a need for competition."

> Can tethering of Swi6 to chromatin recruit Epe1 in the absence of H3K9me? I feel that the authors\' model needs substantially more support than is currently provided.

We interpreted this request by the reviewer as having to show further evidence for the non-enzymatic properties of Epe1 by developing new phenotypic assays. We were inspired by this question to design the experiment detailed in this response.

Two hybrid experiments where Epe1 is fused to an activation domain and Swi6 is fused to a DNA binding domain detect a direct interaction between the two proteins (Sorida et al., 2019; Braun et al., 2011). The two hybrid assay also detects a loss of interaction between Epe1 JmjC mutants and Swi6 (Sorida et al., 2019). Therefore, tethering Swi6 to chromatin can recruit Epe1 to activate reporter gene expression in budding yeast cells which lack H3K9 methylation. However, these findings are not at all in conflict with our data. We clearly demonstrate the existence of a weak interaction between Epe1 and Swi6 and then go on to show that this interaction is enhanced in the presence of H3K9 methylation (Figure 2 and Figure 5). Since our reconstitution experiments are performed in the absence of any additional cellular factors, we believe that our measurements a unique feature of Epe1 that cannot be detected using genetic assays.

Furthermore, we designed a completely novel ectopic silencing approach in fission yeast to provide additional evidence for a non-catalytic function associated with the Epe1 C-terminus. Since Epe1 interacts with Swi6 and excludes other effector molecules, we hypothesized that Swi6 mediated heterochromatin initiation would be highly sensitive to Epe1 activity (enzymatic or non-enzymatic). Tethering Swi6 at an ectopic site does not lead to heterochromatin establishment in fission yeast. Deleting *epe1*D was sufficient to trigger heterochromatin assembly and mediate epigenetic inheritance where silencing is maintained in the absence of the initiator. Next, we expressed the C-terminus of Epe1 (434-948) which lacks the JmjC domain in cells where a TetR-Swi6 CSD fusion has been tethered. The C-terminal fragment expression now completely blocks heterochromatin formation at the ectopic site. These results clearly support a model where the non-enzymatic function of Epe1 relies on its Swi6 interaction. Our in vitroand in vivodata seek to demonstrate how modified chromatin domains provide a context where this interaction is significantly strengthened.

> Reviewer \#2:
>
> In fission yeast, Epe1 is a putative histone demethylase that plays important roles in regulating the heterochromatin landscape. However, the mechanism by which Epe1 functions is not clear.
>
> In this manuscript, the authors found that point mutations that abolish co-factor binding in the JmjC domain can disrupt Epe1\'s binding with Swi6 and also reduces Epe1 localization at heterochromatin. in vitro binding assays confirmed that one Epe1 mutant (H297A) has significantly reduced binding with Swi6. Truncation analysis mapped the Swi6 interaction interface to Epe1 433-630, which is outside of the JmjC domain. Moreover, Epe1 433-630 interacts with Swi6 stronger than full length Epe1, which led the authors to hypothesize that full-length Epe1 might adopt an auto-inhibitive conformation to prevent its binding with Swi6. Indeed, the authors found that Epe1\'s N-terminal region can bind to its C-terminal region. Authors further demonstrated that H3K9me3 is required for Swi6-Epe1 interaction in vivo and that H3K9me3 peptide enhanced Swi6-Epe1 interaction in vitro, but not Epe1-H29&A. These results suggest a mechanism for Epe1 to only interact with Swi6 at heterochromatin regions. Lastly, the authors showed that Epe1 blocks Swi6\'s interaction with Clr3, an HDAC important for heterochromatin assembly.
>
> Overall, the data quality is high and the proposed model is very interesting. The findings will be of high interest to the heterochromatin field. I would recommend its publication after addressing several major questions.
>
> 1\) The model suggests that the JmjC domain of Epe1 binds to H3K9me3 and that the H297A mutation affects this binding. Since the authors have recombinant proteins at hand, they should test these interactions.

We tested the direct interaction between Epe1 and an H3K9me3 peptide and H3K9 methylated histones. Our binding assays clearly detect a direct interaction between Epe1 and an H3K9me3 peptide as opposed to an unmodified H3K9me0 peptide. Furthermore, Epe1 selectively interacts with H3K9 methylated histones as opposed to H3K4 methylated histones. These data have now been added to the revised version of the manuscript (Figure 2---figure supplement 1H and I).

> 2\) The model also suggests that in the presence of H3K9me3, interaction between Epe1\'s N- and C-terminal regions will be reduced. This should also be tested.

To test whether H3K9 methylation releases an auto-inhibitory conformation of Epe1, we measured the interaction between the N- and C-terminal Epe1 fragments in the presence or absence of an H3K9me3 peptide. The addition of an H3K9me3 peptide disrupts the direct interaction between the N- and C-terminal Epe1 fragments in *trans.* This data has now been added to the revised version of the manuscript (Figure 5A).

> 3\) In Figure 4, there appears to be very weak binding of WT Epe1 with Swi6 without H3K9me3 peptide. This is very different from results shown in Figures 2 and 3. What\'s the reason for this discrepancy?

We apologize to the reviewer for the lack of clarity in our presentation. This difference is due to the use of chemiluminescent based western blot assays to measure binding efficiencies. We have explicitly stated that these assays are semi-quantitative in the manuscript text although we do obtain trends based on adding different Epe1 protein concentrations. Although samples in the same blot can be compared, we cannot compare samples loaded on different gels.

In Figure 2E where we compare the interaction between wild-type Epe1 and Epe1 H297A we use high exposure times to reveal a difference in binding. To demonstrate a stimulation in the interaction between Epe1 and Swi6 in the presence of an H3K9me3 peptide, we used a low exposure time so that the assay is sensitive to reveal a substantial change in binding upon peptide addition. In this assay as well, the difference between wild-type Epe1 and Epe1 H297A binding to Swi6 is still visible but less prominent (Figure 4E).

We have now included an additional statement in our Materials and methods section regarding how we choose exposure times to capture differences in binding interactions. The Materials and methods section describing how we setup our binding assays has been amended as follows:

"The exposure times for the interaction assays were chosen and differ in each experiment in order to capture differences in the interaction between Epe1 and Swi6 depending on the assay conditions. Assays performed on different blots cannot be compared but samples loaded on the same blot can be readily compared to each other".

> 4\) Clr3∆ or Sir2∆ has different effects on H3K9me at centromeres, mating type region, and telomeres. If the hypothesis is correct, it is expected that Epe1 localization will change differently at different locations. ChIP analysis of Epe1 will complement Figure 4B and strengthen the hypothesis.

We are very grateful to the reviewer for this suggestion. We deleted *clr3∆* in strains expressing Epe1-3XFLAG. We cross-linked cells with formaldehyde and performed ChIP experiments to map Epe1 localization at the pericentromeric repeats, mating-type locus and the telomeres. The *dg* repeats exhibit a 2-3 fold increase in Epe1 localization in *clr3*Δcells (Shimada et al.). This increase is consistent with a model where Clr3 and Epe1 trade places at sites of heterochromatin formation. Epe1 localization also exhibits a two-fold increase at the mating type locus in strains where the *cenH* nucleation site is intact. Deleting *clr3*Δ causes a complete loss of Epe1 localization at the telomeres consistent with a critical role for the SHREC complex in telomere silencing (Sugiyama et al., 2007).

> Reviewer \#3:
>
> The putative histone demethylase Epe1 in fission yeast has been shown to localize heterochromatin via interaction with a HP1 homologue Swi6 and antagonize heterochromatin formation probably through its JmjC-domain dependent demethylation activity, though the enzymatic activity has not been detected in vitro. In this manuscript, authors made several interesting observations. (1) JmjC-domain mutants of Epe1 loose interaction with Swi6 and heterochromatin localization. (2) Epe1 interacts with Swi6 via its C-terminal half that does not include JmjC domain. (3) Epe1 N-terminal half including JmjC-domain interacts with C-terminal half in trans. (5) H3K9me peptide enhance interaction between Swi6 and Epe1. (4) Expression of C-terminal half Epe1 antagonize maintenance of heterochromatic silencing with non-enzymatic activity. (6) Mutation of JmjC domain strengthen the interaction between Swi6 and Clr3, a Swi6-binding silencing factor. (7) Artificial recruitment of Clr3 supports maintenance of heterochromatin in the presence of wild type Epe1. Taken together authors claimed that Epe1-Swi6 binding is auto-inhibited by cis-interaction between N-terminal half and C-terminal half of Epe1. The auto-inhibition can be released by H3K9 methylation and Epe1 compete with Clr3 for Swi6-binding resulting in removal of heterochromatin.

We are very grateful to Dr. Murakami for his encouraging and positive comments regarding our manuscript. Furthermore, we were not aware of a publication from his lab (Sorida et al., 2019) relating to the non-enzymatic functions of Epe1 at the time of submission. We have corrected this oversight on our part. We have also highlighted areas of overlap and how both our studies collectively add important mechanistic insight relating to the non-enzymatic functions of Epe1 (albeit using different phenotypic assays). We have attempted to address all of the major revisions outlined in Dr. Murakami's scholarly critique.

> Author\'s model is novel and interesting in terms of regulatory mechanism of heterochromatin by Epe1. However, their model is not fully supported by their experimental data. There is no direct evidence showing Epe1 N-terminal half and C-terminal half interacts in cis. Their result can be also explained by trans-interaction. Moreover, they did not present direct evidence showing this interaction is inhibitory to Swi6 binding. This could be tested by adding N-terminal half in the in vitro binding assay of Epe1^434-948^ and Swi6 (Figure 3A). In addition, If H3K9me peptide release the auto inhibition through Epe1 as author claimed, addition of H3K9me peptide in the in vitro binding assay would disrupt interaction between N- and C-terminal half of Epe1.

We thank Dr. Murakami for his positive feedback about our manuscript. We have added additional experiments that lends strong support to our model. To test whether H3K9 methylation releases an auto-inhibitory conformation of Epe1, we measured the interaction between the N- and C-terminal Epe1 fragments in the presence or absence of an H3K9me3 peptide. First, we purified Epe1 (1-434) from fission yeast cells using 3XFLAG epitope tag. Despite protein expression being low in fission yeast cells, we obtained sufficient quantities of the N-terminal fragment in order to setup in vitrobinding assays. Next, we added a recombinant Epe1 (434-948) protein fragment purified from *E. coli*. We performed experiments in the presence and absence of an H3K9me3 peptide. The addition of an H3K9me3 peptide disrupts a direct interaction between the N- and C-terminal Epe1 fragments in *trans.* This data has now been added to the revised version of the manuscript (new Figure 5A). This data strongly supports our hypothesis where an interaction between the Epe1 N- and C-terminal halves is dependent on H3K9 methylation.

> Furthermore, I think one of the main point of their model is that competition between Epe1 and Clr3 for Swi6, by which Epe1 inhibits stable maintenance of artificially formed heterochromatin. However, the evidence for this mechanism is not enough. At least, they should check localization of Clr3 at artificial heterochromatin by ChIP analysis. If their model is correct, amount of Clr3 at artificial heterochromatin (-Tet) would increase in epe1∆ or epe1-H297A cells and decreased in the presence of Epe1 or Epe1^434-948^.

Our conclusions in this part of the manuscript builds on previous studies revealing an interplay between Epe1 and Clr3 in localizing at sites of heterochromatin formation (Shimada et al., 2009). Inspired by this study, we tested whether Clr3 could interact with Swi6 and how this interaction is altered in an Epe1 JmjC mutant background (Figure 6A).

To test whether Clr3 binding is critical to preserve epigenetic memory, we fused a 3X-V5 epitope tag to the Clr3 C-terminus and performed ChIP experiments in cells expressing WT Epe1 or an Epe1 H297A mutant. The V5 epitope tag was chosen since it is orthogonal to other FLAG tagged constructs that are expressed in this strain background. We performed ChIP experiments using formaldehyde or after adding reactive cross-linkers in addition to formaldehyde. Under both conditions, we were unable to detect Clr3 enrichment at the ectopic site relative to controls where Clr4 is absent. Furthermore, we note that this problem was not unique to the ectopic locus since we also could not detect significant Clr3 enrichment at the *dg* repeats compared to *clr4*Δcontrol strains. We compared our studies to those performed by other groups including Dr.Murakami's lab (Shimada et al., 2010). One important difference is the use a 3X FLAG epitope tag versus a 3X V5 epitope tag.

However, we would like to emphasize that our ectopic system is explicitly dependent on Clr3 for heterochromatin establishment. The deletion of *clr3*Δleads to a complete loss of epigenetic silencing where cells turn white in the absence of tetracycline (Ragunathan et al., 2015). The deletion of Epe1 (*epe1*D *clr3*Δ)cannot rescue this loss of silencing. Therefore any circumstance where we see maintenance mandates the presence of Clr3. We fully expect that our ChIP experiments will conform to the proposed model where Epe1 and Clr3 trade places while interacting with Swi6 to preserve epigenetic memory. Additional experiments requested by reviewer 2 (new Figure 6C-E) also support this hypothesis.

> Recent paper (Sorida et al., 2019), showed that N-terminal domain that does not include jmjC domain has transcription activation activity and deletion of this domain caused severe loss of Swi6 binding and heterochromatin localization of Epe1. In addition, they showed H297A mutation also caused reduction of Swi6 binding. Probably, this paper published after the submission of this manuscript, but authors should mention and discuss about this paper in the revised manuscript.

We apologize to Dr. Murakami for this oversight. We were not aware of the publication of this manuscript at the time of our submission. In combination with Bao et al., 2019; we believe that the publication of our manuscript will be a timely addition to demonstrate how a broad spectrum of non-enzymatic functions associated with Epe1 affect the establishment and maintenance of epigenetic silencing in fission yeast cells.

\[Editors' note: what follows is the authors' response to the second round of review.\]

> Essential revisions:
>
> 1\) The most important outstanding concern is about the interaction between H3K9me3 and Epe1. This interaction is central to the authors\' hypothesis yet is tested only with the entire Epe1 protein and reported in two supplementary panels. One concern is that the model presented by the authors -- that Swi6 and Epe1 may not compete for H3K9me tails -- depends on the binding affinities of these proteins for H3K9me. There are significantly fewer H3K9me tails (\~2000 nucleosomes) in fission yeast than Swi6 molecules (\~20,000, Sadaie, 2008), which would argue that only molecules at the affinity of Swi6 for H3K9me2/3, or tighter, could access tails. Co-occupancy of Swi6 and Epe1 of adjacent tails therefore is possible only in a circumstance where the affinity of Epe1 is at least as high as that of Swi6 (which is not terribly high, measured at \~2-15 µM depending on the group), given the substantial Swi6 excess. The easiest way to show that H3K9me binding by Epe1 directs its assembly on chromatin is to mutate the region or residues required for this recognition and test its impact.
>
> Given the many available truncation constructs, the authors should be able to identify the domain that interacts with H3K9me and determine the affinity of the interaction. As previously suggested, the JmjC domain is a good candidate for H3K9me binding. These data could be used to generate a mutant that abolishes binding, and the mutant phenotypes should be tested in vivo. These experiments would be very important to support the authors\' conclusions.

We thank the reviewers for their scholarly comments and for highlighting a major point of interest in our manuscript. We have generated new supporting data to highlight the unique H3K9me specific binding properties associated with Epe1. We have also elevated the importance of these findings by relocating the peptide binding and histone binding assay to the main figure panel (new Figure 5).

The previous version of our manuscript established that the full-length Epe1 protein preferentially interacts with an H3K9me3 peptide (Figure 5A) and specifically binds to H3K9me3 histones (as opposed to an H3K4me3 histone, Figure 5B). Now, we have used a C-terminal truncation mutant of Epe1 (Epe1-ΔC) to test whether the H3K9me3 binding activity resides within the N-terminus of the protein. Indeed, the Epe1-ΔC protein (deletion of the Epe1 C-terminus, 600-948 amino acids) exhibits a preferential interaction with an H3K9me3 peptide (new Figure 5---figure supplement 1A) and specifically binds to H3K9me3 histones (new Figure 5---figure supplement 1B). Since the N-terminal fragment of Epe1 includes the putative catalytic JmjC domain, we are fully in agreement with reviewers that this domain might be directly responsible for H3K9me binding.

To purify The JmjC domain of Epe1 and design mutants to test H3K9 methylation binding, we dedicated considerable effort to test different solubility and affinity tags in *E. coli* for recombinant protein expression. However, despite our best efforts we were unable to purify sufficient amounts of recombinant Epe1 protein required for rigorous affinity measurements using either ITC or fluorescence polarization. Therefore, we are unable to compare and report the absolute H3K9 methylation binding affinities associated with Epe1 and Swi6.

However, we fully recognize the importance of this question raised by the reviewers and endeavored to provide further support for our proposed model. Swi6 is preserved in an auto-inhibited state through interactions between adjacent chromodomains (Canzio et al., 2013). A Swi6 Loop-X mutation (Swi6 R93A K94A) releases the chromodomain from an auto-inhibited conformation enabling increased engagement with an H3K9me3 peptide. Despite the lack of auto-inhibition, the interaction between Epe1 and a Swi6 Loop-X mutant is also stimulated by the presence of an H3K9me3 peptide (new Figure 4---figure supplement 1E). Therefore, Epe1 remains responsive to the presence of an H3K9 methylated peptide even in an experimental context where Swi6 is constitutively released from auto-inhibition.

The central premise of our model is that H3K9 methylation acts via Epe1 to stimulate complex formation with Swi6. Our multi-pronged genetic and biochemical analyses provide strong evidence in favor of this model. We believe that the lack of affinity measurements does not detract from the major conclusions in our revised submission.

> 2\) The presented data clearly indicate that an H3K9me peptide can disrupt the interaction between the N-terminal and C-terminal domains of Epe1. However, the authors have not tested if the addition of the N-terminal half inhibits the interaction between the C-terminus and Swi6. This would provide support for the authors\' autoinhibition model.

We thank the reviewers for suggesting a key experiment that would lend additional support for our model of H3K9 methylation dependent regulation of Epe1 activity. Our previous studies demonstrated that the N-terminal fragment of Epe1 (1-434 amino acids) interacts with a C-terminal fragment (434-948 amino acids) in *trans.* We also observed that the addition of an H3K9me3 peptide but not an H3K9me0 peptide disrupts a *trans* interaction between the two protein fragments (Figure 5C). We purified limited quantities of the Epe1-N (1-434) fragment using an M2 FLAG antibody. The protein was retained on beads and immediately used for subsequent binding assays. We added recombinant MBP-Epe1-C (434-948) in the presence of 1.5-2 fold molar excess of Swi6 (or control experiments where Swi6 was left out). Our in vitro binding experiments demonstrate that Swi6 could also efficiently disrupt complex formation between the Epe1 N-terminus and C-terminus in *trans* (new Figure 3B).

> 3\) The presented experiments strongly suggest, but do not prove, an autoinhibitory mechanism, as there are no experiments that directly address Epe1 conformation. Therefore, claims regarding such a mechanism should be softened. The title could be changed to \"Interaction with histone H3 methylated at lysine 9 regulates the non-enzymatic functions of the putative histone demethylase Epe1\" or something similar, and strong claims like \"An auto-inhibitory conformation regulates the non-enzymatic properties of Epe1 through its interaction with Swi6\" in the Abstract should be amended or removed.

We appreciate the reviewers' insights and have amended our manuscript by discussing our results as H3K9 methylation dependent changes in protein-protein interactions between Epe1 and Swi6. Consistent with the suggestions provided, we have revised the title and the Abstract of our revised submission.
